<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">86125</article-id><article-id pub-id-type="doi">10.7554/eLife.86125</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-304403"><name><surname>Croft</surname><given-names>Wayne</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6780-5944</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-304406"><name><surname>Pearce</surname><given-names>Hayden</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8380-8122</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304407"><name><surname>Margielewska-Davies</surname><given-names>Sandra</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5115-470X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304408"><name><surname>Lim</surname><given-names>Lindsay</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1394-3297</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304409"><name><surname>Nicol</surname><given-names>Samantha M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304410"><name><surname>Zayou</surname><given-names>Fouzia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304411"><name><surname>Blakeway</surname><given-names>Daniel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9501-7451</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304412"><name><surname>Marcon</surname><given-names>Francesca</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7439-8291</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304510"><name><surname>Powell-Brett</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304516"><name><surname>Mahon</surname><given-names>Brinder</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304512"><name><surname>Merard</surname><given-names>Reena</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-192178"><name><surname>Zuo</surname><given-names>Jianmin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304513"><name><surname>Middleton</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304514"><name><surname>Roberts</surname><given-names>Keith</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304515"><name><surname>Brown</surname><given-names>Rachel M</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-148122"><name><surname>Moss</surname><given-names>Paul</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6895-1967</contrib-id><email>p.moss@bham.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03angcq70</institution-id><institution>Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham</institution></institution-wrap><addr-line><named-content content-type="city">Birmingham</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03angcq70</institution-id><institution>Centre for Computational Biology, University of Birmingham</institution></institution-wrap><addr-line><named-content content-type="city">Birmingham</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tnbqb63</institution-id><institution>Cancer Research Horizons, The Francis Crick Institute</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/048emj907</institution-id><institution>University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham</institution></institution-wrap><addr-line><named-content content-type="city">Birmingham</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Macleod</surname><given-names>Kay F</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024mw5h28</institution-id><institution>University of Chicago</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ng</surname><given-names>Tony</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>23</day><month>06</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e86125</elocation-id><history><date date-type="received" iso-8601-date="2023-01-11"><day>11</day><month>01</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-06-22"><day>22</day><month>06</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2023-01-21"><day>21</day><month>01</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.01.20.524883"/></event></pub-history><permissions><copyright-statement>© 2023, Croft, Pearce et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Croft, Pearce et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-86125-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-86125-figures-v2.pdf"/><abstract><p>Pancreatic ductal adenocarcinoma has a poor clinical outcome and responses to immunotherapy are suboptimal. Stromal fibroblasts are a dominant but heterogenous population within the tumor microenvironment and therapeutic targeting of stromal subsets may have therapeutic utility. Here, we combine spatial transcriptomics and scRNA-Seq datasets to define the transcriptome of tumor-proximal and tumor-distal cancer-associated fibroblasts (CAFs) and link this to clinical outcome. Tumor-proximal fibroblasts comprise large populations of myofibroblasts, strongly expressed podoplanin, and were enriched for Wnt ligand signaling. In contrast, inflammatory CAFs were dominant within tumor-distal subsets and expressed complement components and the Wnt-inhibitor SFRP2. Poor clinical outcome was correlated with elevated HIF-1α and podoplanin expression whilst expression of inflammatory and complement genes was predictive of extended survival. These findings demonstrate the extreme transcriptional heterogeneity of CAFs and its determination by apposition to tumor. Selective targeting of tumor-proximal subsets, potentially combined with HIF-1α inhibition and immune stimulation, may offer a multi-modal therapeutic approach for this disease.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Pancreatic cancer is one of the deadliest and most difficult cancers to treat. It responds poorly to immunotherapy for instance, despite this approach often succeeding in enlisting immune cells to fight tumours in other organs. This may be due, in part, to a type of cell called fibroblasts. Not only do these wrap pancreatic tumours in a dense, protective layer, they also foster complex relationships with the cancerous cells: some fibroblasts may fuel tumour growth, while other may help to contain its spread.</p><p>These different roles may be linked to spatial location, with fibroblasts adopting different profiles depending on their proximity with cancer calls. For example, certain fibroblasts close to the tumour resemble the myofibroblasts present in healing wounds, while those at the periphery show signs of being involved in inflammation. Being able to specifically eliminate pro-cancer fibroblasts requires a better understanding of the factors that shape the role of these cells, and how to identify them.</p><p>To examine this problem, Croft et al. relied on tumour samples obtained from pancreatic cancer patients. They mapped out the location of individual fibroblasts in the vicinity of the tumour and analysed their gene activity. These experiments helped to reveal the characteristics of different populations of fibroblasts. For example, they showed that the myofibroblast-like cells closest to the tumour exhibited signs of oxygen deprivation; they also produced podoplanin, a protein known to promote cancer progression. In contrast, cells further from the cancer produced more immune-related proteins.</p><p>Combining these data with information obtained from patients’ clinical records, Croft et al. found that samples from individuals with worse survival outcomes often featured higher levels of podoplanin and hypoxia. Inflammatory markers, however, were more likely to be present in individuals with good outcomes.</p><p>Overall, these findings could help to develop ways to selectively target fibroblasts that support the growth of pancreatic cancer. Weakening these cells could in turn make the tumour accessible to immune cells, and more vulnerable to immunotherapies.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>pancreatic cancer</kwd><kwd>PDAC</kwd><kwd>cancer-associated fibroblasts</kwd><kwd>NanoString GeoMx</kwd><kwd>tumour microenvironment</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>A21135</award-id><principal-award-recipient><name><surname>Croft</surname><given-names>Wayne</given-names></name><name><surname>Pearce</surname><given-names>Hayden</given-names></name><name><surname>Margielewska-Davies</surname><given-names>Sandra</given-names></name><name><surname>Lim</surname><given-names>Lindsay</given-names></name><name><surname>Nicol</surname><given-names>Samantha M</given-names></name><name><surname>Middleton</surname><given-names>Gary</given-names></name><name><surname>Roberts</surname><given-names>Keith</given-names></name><name><surname>Moss</surname><given-names>Paul</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010665</institution-id><institution>European Union Horizon 2020 Marie Skłodowska-Curie Actions PAVE</institution></institution-wrap></funding-source><award-id>861190</award-id><principal-award-recipient><name><surname>Zayou</surname><given-names>Fouzia</given-names></name></principal-award-recipient></award-group><funding-statement>This independent research was carried out at the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Profiling spatially defined fibroblasts in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment identifies high levels of podoplanin and hypoxia in tumor-proximal fibroblasts associated with bad prognosis, whilst inflammatory markers define more distal fibroblast regions and associate with better outcomes.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Therapeutic control of pancreatic ductal adenocarcinoma (PDAC) is one of the greatest challenges in oncology and PDAC remains associated with poor long-term survival (<xref ref-type="bibr" rid="bib2">Arnold et al., 2019</xref>). Although immunotherapy has transformed the clinical outlook for many tumor subtypes its impact on PDAC has been disappointing to date. One factor in this regard may be the characteristic nature of the PDAC microenvironment which is associated with an intense desmoplastic reaction characterized by an abundance of cancer associated fibroblasts (CAF; <xref ref-type="bibr" rid="bib6">Biffi and Tuveson, 2021</xref>; <xref ref-type="bibr" rid="bib29">Menezes et al., 2022</xref>).</p><p>Fibroblasts are key regulators of tumor biology and there is now intense interest in understanding how they may act to maintain or suppress tumor growth. CAF are the predominant source of extracellular matrix and develop a complex system of interactions with tumor cells. Although some of the characteristics of CAF suggest chronic activation with sustained production of alpha-small muscle actin(α-SMA), they differ from normal counterparts by relative resistance to apoptosis or reversion of quiescence (<xref ref-type="bibr" rid="bib37">Piersma et al., 2020</xref>). PDAC-associated CAF can limit the access of immune effector cells to tumor (<xref ref-type="bibr" rid="bib31">Mhaidly and Mechta-Grigoriou, 2021</xref>; <xref ref-type="bibr" rid="bib21">Inoue et al., 2016</xref>; <xref ref-type="bibr" rid="bib14">Ene-Obong et al., 2013</xref>), promote the infiltration of immune suppressive leucocyte populations and directly support tumor growth (<xref ref-type="bibr" rid="bib25">Kumar et al., 2017</xref>; <xref ref-type="bibr" rid="bib1">Albrengues et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Mezawa and Orimo, 2016</xref>; <xref ref-type="bibr" rid="bib16">Fang et al., 2019</xref>). However, studies from murine models have also shown that fibroblasts may also play a protective role in limiting tumor metastasis and that targeting of stromal cells can accelerate disease progression (<xref ref-type="bibr" rid="bib35">Özdemir et al., 2014</xref>). Furthermore, a clinical trial that targeted CAF through inhibition of the hedgehog protein, combined with chemotherapy, was terminated early due to disease progression (<xref ref-type="bibr" rid="bib9">Catenacci et al., 2015</xref>). One suggestion has been that fibroblasts may play an important role in constraining the growth of of early-stage tumors but subsequently become subverted to support tumor progression (<xref ref-type="bibr" rid="bib29">Menezes et al., 2022</xref>). As such, effective fibroblast-targeted therapies will need to be directed selectively towards those subpopulations that are critical to support tumor growth.</p><p>Transcriptional analyses have shown at least four subsets of CAF in PDAC with a heterogenous profile and direct associations with clinical outcome (<xref ref-type="bibr" rid="bib30">Mezawa and Orimo, 2016</xref>). Spatially related features are also observed with α-SMA<sup>high</sup> myofibroblast populations closely associated with tumor whilst inflammatory subsets reside more distally (<xref ref-type="bibr" rid="bib34">Öhlund et al., 2017</xref>). Cytokines such as TGF and IL-1 appear as key regulators and may direct differentiation from a CD105 +precursor (<xref ref-type="bibr" rid="bib12">Dominguez et al., 2020</xref>). Marked cellular plasticity is a feature of CAF (<xref ref-type="bibr" rid="bib32">Neuzillet et al., 2019</xref>), although it remains unclear if CAF develop discrete lineages or are interchangeable. Within PDAC a population of LRRC15<sup>+</sup> myofibroblasts is emerging as a potential tumor-associated subset with direct impact on clinical responses to therapy (<xref ref-type="bibr" rid="bib12">Dominguez et al., 2020</xref>).</p><p>Immunotherapy trials in PDAC indicate that multi-modal approaches may be required for effective therapy and therapeutic targeting of CAF subpopulations could contribute to this. Here, we combine spatial transcriptomics with a scRNA-Seq dataset to define the transcriptome of tumor-proximal and tumor-distal fibroblasts within the PDAC microenvironment. Furthermore, these studies were correlated with clinical outcome and revealed that elevated podoplanin and HIF-1α expression were markers of poor outcome whilst expression of immunoregulatory genes correlates with favorable long-term response. These findings provide insight into stromal architecture in PDAC and could help to guide therapeutic approaches to target pro-tumorigenic fibroblast subsets.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Spatially defined stromal and immune regions can be characterized within the PDAC microenvironment</title><p>Histological slide sections were obtained from tumor biopsies of 24 patients with pancreatic ductal adenocarcinoma (PDAC) who had undergone surgical resection for localized disease. Thirteen patients had died of PDAC within 12 months of diagnosis (subsequently referred to as ‘poor response’) whilst 11 had survived for at least 36 months (‘good response’).</p><p>Four-plex immunofluorescence staining was used initially to define major anatomical subregions of the tumor. Antibodies against pan-cytokeratin, α-SMA and CD45 identified epithelial, fibroblast and immune populations respectively whilst DAPI staining defined nuclear architecture. Regions in which stromal cells were adjacent to tumor (‘tumor-proximal stroma’), distant from tumor (‘tumor-distal stroma’) or enriched for CD45+ immune cells (‘immune enriched’) were then selected and 4 areas (‘regions of interest’; ROI) within each of these 3 domains were selected from each patient for assessment using the NanoString GeoMx Digital Spatial Profiler (DSP) platform (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Schematic representation of experimental approach.</title><p>Histological slides of 24 surgical resection specimens from patients with PDAC were stained with DAPI (‘nuclear’), anti-pan-CK (‘epithelial’), anti-α-SMA (‘fibroblast’) and anti-CD45 (‘immune’) to identify tumor cells and primarily to define three domains: ‘tumor-proximal stroma’ (PS), ‘tumor-distant stroma’ (DS) and ‘immune-enriched’ (I). The NanoString Immuno-oncology RNA probe set, in combination with a custom panel of 10 fibroblast-targeted RNA probes, was used to interrogate four areas (termed ‘Regions of Interest’; ROI) from each of the three domains using the NanoString GeoMx Digital Spatial Profiler (DSP) platform. The transcriptional profile of spatially-defined tumor-proximal or tumor-distant fibroblast cells was subsequently aligned to scRNA-Seq datasets from three additional patients with PDAC.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig1-v2.tif"/></fig><p>Ninety-four RNA hybridization probes (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref> and <xref ref-type="fig" rid="fig2s2">2</xref>) for 81 endogenous, 6 housekeeping and 7 negative control genes were then applied to the 12 ROI from each patient, thus generating 288 transcriptional datasets. Six pan-cytokeratin positive ROI were also selected to define the transcriptional profile of tumor cells.</p><p>Hierarchical clustering of transcriptional datasets delineated immune and stromal regions with two immune profiles clustering separately due to differential expression of activatory and inhibitory immune genes. Cell-type expression profiles were consistent with immune or stromal origin (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). UMAP analysis broadly separated tumor, proximal stroma, distal stroma, and immune regions (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), although overlay of clinical outcome data did not reveal significant clustering.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Overview of gene expression data from spatially-defined stromal and immune regions within the PDAC tumor microenvironment using NanoString GeoMx DSP.</title><p>(<bold>A</bold>) Expression profile of all endogenous probes across regions of interest (ROI) with hierarchical clustering of ROIs. (<bold>B</bold>) UMAP embedding from normalized count data showing all ROIs overlaid with ROI-specific annotations of Region (Immune/Stroma/Tumor type) and Survival (1 yr/3 yr). (<bold>C</bold>) Mean normalized count of cell type marker genes within regions. Lines indicate regions from the same patient; dashed line represents mean background threshold from negative probes; Mean +/-SE of mean shown in red. (<bold>D</bold>) Differential expression analysis to identift genes expressed differentially between Immune and Stroma ROIs. Colored points indicate differentially expressed genes (DEG) (BH adjusted p&lt;0.05 and absolute log<sub>2</sub>FC &gt;0.25). (<bold>E</bold>) Immune and Stroma expression signatures from DEGs identified in D.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Raw count expression profiles.</title><p>(<bold>A</bold>) Heatmap of raw expression profile for the complete probeset (colour scale = raw count). (<bold>B</bold>) Per patient (scan) expression distributions for PanCK+ (tumor) and PanCK- (non-tumor) regions of interest. (<bold>C</bold>) Per patient (scan) expression profiles (mean +/-SE) for Endogenous, Housekeeping and Negative control probesets.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Housekeeping gene correlations and data normalisation.</title><p>(<bold>A</bold>) Pairwise correlation scatter plots for 6 housekeeping control probes. Raw housekeeping gene counts from all regions of interest (ROIs) were correlated against each other. Plots display the scatter, distribution histogram and Pearson correlation coefficient and significance (***p&lt;0.001). (<bold>B</bold>) Relative log expression plots of raw count data and post normalization with the top two most-correlated housekeeping genes (H3F3A and UBB) to remove unwanted variation (RUV method).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Correlation matrix of endogenous probes.</title><p>Pairwise correlations of normalized gene count data represented as a matrix of Pearson correlation coefficients.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig2-figsupp3-v2.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Individual gene expression profiles on UMAP embeddings of all regions of interest (ROIs).</title><p>UMAP embedding generated from normalized count data of all probes in all REIs overlaid with ROI-specific normalized gene count.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig2-figsupp4-v2.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>High level cell type contexture of PDAC tumor microenvironment.</title><p>(<bold>A</bold>) (left), UMAP embedding of transcriptional data for 17,958 cells in the tumor microenvironment of 3 x PDAC patient tissue samples overlaid with high level cell type identified from unsupervised clustering. A (right), UMAP embedding overlaid with source sample identifier. (<bold>B</bold>) UMAP embedding overlaid with the expression profile of canonical high level cell type marker genes. (<bold>C</bold>) Average scRNA expression profile of spatial profiling defined Immune and Stroma ROI type-associated genes within high level cell types defined by scRNA-seq (n=3 PDAC samples).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig2-figsupp5-v2.tif"/></fig></fig-group><p>Expression of cell lineage marker genes was then used to determine the relative localization of cell subsets within proximal-stromal, distal-stromal, immune or tumor regions of interest (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). These confirmed localization of epithelial, fibroblast and lymphoid cells within the tumor, stromal and immune regions respectively whilst monocyte representation was equivalent within stromal and immune regions, consistent with broad infiltration within PDAC microenvironment. CD3E and MS4A1 expression indicated that stromal regions also contained smaller populations of infiltrating T and B cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Distinct modules of genes co-expressed with lineage markers could also be identified and were consistent with cell type (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Stromal regions expressed canonical fibroblast markers such as THY1, PDPN, and FAP whilst immune-specific genes such as PTPRC, CD3E and MS4A1 were present within Immune regions (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>, <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>).</p><p>To align the regional transcriptional landscape to specific cell subsets, RNA expression profiles defined by NanoString DSP analysis were mapped onto an additional scRNA-Seq dataset derived from three additional patients (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5</xref>; <xref ref-type="bibr" rid="bib36">Pearce et al., 2023</xref>). This revealed that, whilst the great majority of stromal-associated genes were expressed from fibroblasts, the expression of <italic>CSF1R</italic> within stroma was largely derived from myeloid cells, <italic>CTNNB1</italic> localized to endothelial cells and expression of <italic>KRT</italic> was identified as <italic>KRT18</italic> within epithelial cells (<xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5C</xref>).</p></sec><sec id="s2-2"><title>The transcriptional profile of stromal regions is strongly determined by proximity to tumor</title><p>We next went on to assess gene expression within stroma in relation to proximity to tumor (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Transcriptional profiles were seen to vary markedly between tumor-proximal or tumor-distal ROI. In particular, expression of <italic>DKK3</italic> and <italic>PDPN</italic> was markedly increased in stroma-proximal regions (<xref ref-type="fig" rid="fig3">Figure 3A, B and C</xref>) and both are established markers of cancer-associated fibroblasts implicated in support of tumor growth (<xref ref-type="bibr" rid="bib51">Zhou et al., 2018</xref>; <xref ref-type="bibr" rid="bib20">Hirayama et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Shindo et al., 2013</xref>). In contrast, expression of <italic>C3, SFRP2, STAT3</italic>, <italic>IL-6</italic> and <italic>THY1</italic> was increased in tumor-distal stroma. <italic>C3</italic> and <italic>SFRP2</italic> expression were particularly elevated (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) and localization of C3 expression to fibroblasts was further suggested by correlation with fibroblast, but not monocyte, marker genes (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). This is noteworthy given the emerging importance for intracellular complement expression and the action of SFRP2 as a Wnt inhibitor. STAT3 and IL-6 expression could be explained by their presence within inflammatory CAFs whilst THY1 is commonly expressed on stem-like populations of fibroblasts (<xref ref-type="bibr" rid="bib45">Shi et al., 2019</xref>). The stem cell marker CD34 was also expressed in this region (<xref ref-type="fig" rid="fig3">Figure 3A, B and C</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Expression signature of PDAC tumor-proximal and tumor-distal stromal cells.</title><p>(<bold>A</bold>) Differentially expressed genes (DEGs) between stroma regions proximal (P) or distal (D) from tumor. Colored points indicate differentially expressed genes (BH adjusted <italic>P</italic>&lt;0.05 &amp; absolute log<sub>2</sub>FC &gt;0.25). (<bold>B</bold>) Stroma proximity-to-tumor expression signature from DEGs identified in A. (<bold>C</bold>) Relative expression of genes within four PDAC regions: Tumor (T), proximal-tumor stroma (PS), distal-tumor stromal (DS) and immune (<bold>I</bold>). Lines indicate paired regions from the same patient; dashed line represents mean background threshold from negative probes; Mean +/-SE of mean shown in red. Shown as within patient mean normalized count vs region type for DEG identified in A. (<bold>D</bold>) Representative immunohistochemical staining of podoplanin, DKK3 and C3 proteins in relation to tumor cells (T) in PDAC tissue.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Correlations of proximity specific markers DKK3 and C3.</title><p>Pairwise Pearson correlations of tumor-proximity specific markers C3 and DKK3 against marker genes for Lymphocytes, Monocytes and Fibroblast cells. Coefficients are highlighted where there are significant correlations of either DKK3 or C3 within Proximal (green) or Distant (orange) Stroma ROIs.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig3-figsupp1-v2.tif"/></fig></fig-group><p>Immunohistochemical staining confirmed extreme polarization of podoplanin, DKK3 and C3 expression in relation to tumor proximity. Podoplanin was expressed on stroma that encased tumor whilst DKK3 expression was present both within tumor and tumor-proximal stroma. In contrast, expression of C3 was localized to distal stroma regions (<xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p></sec><sec id="s2-3"><title>Mapping of spatial transcriptional profiles on to scRNA-Seq reveals key biochemical pathways associated with proximal and distant fibroblasts</title><p>Given the profound influence of tumor apposition on the NanoString profile of fibroblasts we were interested to explore global fibroblast transcriptome in relation to spatial localization. The minimal NanoString gene set defining proximal and distant fibroblast subsets was therefore explored within the scRNA-Seq dataset from three additional donors (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Two fibroblast clusters were observed from scRNA-Seq unsupervised clustering analysis and defined as sc-proximal and sc-distal populations due to their distinct proximal and distant gene expression signatures (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). Transcriptional profiles were highly divergent between proximal compared to distal clusters with 47 genes differentially upregulated in the distal cluster and 36 genes differentially upregulated in the proximal cluster (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). The sc-proximal clusters showed high expression of myofibroblast (myCAF) marker genes including <italic>MMP11</italic> and <italic>HOPX</italic> whilst the distal population was enriched for expression of genes associated with inflammatory CAF (iCAF) such as <italic>CXCL12</italic> and <italic>CFD</italic> (<xref ref-type="fig" rid="fig4">Figure 4E</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Proximal and Distal Fibroblast populations identified in single cell transcriptome data of PDAC.</title><p>(<bold>A</bold>) Average expression of spatially defined tumor-proximal or tumor-distant stromal genes within cell types defined by scRNA-seq (n=3). (<bold>B</bold>) UMAP embedding of scRNA-Seq data from fibroblasts overlaid with (left to right) expression of the canonical fibroblast marker genes <italic>DCN, LUM and THY1; COL1A2</italic> found in CAFs; gene set variation analysis (GSVA) signature score for tumor-proximal (<italic>DKK3, PDPN, PTENSTAT2, B2</italic> and <italic>STAT1</italic>) or tumor-distal (<italic>STAT3, IL6, C3, VSIR, CD34, CSF1R, THY1, SFRP2</italic>) associated stromal genes; Clustering based on unsupervised Louvain assignment. n=229 Fibroblast cells.(<bold>C</bold>) Average cluster-wise expression profile of selected proximal and distant stroma associated genes as identified by spatial profiling. (<bold>D</bold>) Differential expression analysis between sc-proximal and sc-distant fibroblast cells. Colored points indicate differentially expressed genes (BH adjusted p&lt;0.05 &amp; absolute log<sub>2</sub>FC &gt;0.5). (<bold>E</bold>) Violin plots depicting cluster-wise expression distribution of canonical myCAF and iCAF marker genes. (<bold>F</bold>) GSVA score profiles identified as differentially enriched (BH adjusted p&lt;0.001) in sc-distant vs sc-proximal cells. (<bold>G</bold>) Average within-cluster expression profile of Complement, Retinoic acid metabolism and Wnt ligand biogenesis gene sets. Grey = no detectable expression.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig4-v2.tif"/></fig><p>To investigate the likely functions and master transcription factor regulators that are active for each cluster, differentially enriched pathways, GO-terms and TF target gene sets were identified (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). This showed that sc-proximal fibroblasts are enriched for cell division, chemotaxis and heat shock protein binding. Furthermore, they express a wide range of Wnt ligands including WNT5A, WNT11, WNT2, WNT5, WNT5A and WNT5B (<xref ref-type="fig" rid="fig4">Figure 4F and G</xref>). In contrast, sc-distal fibroblasts show enrichment of pathways associated with generation of the extracellular matrix, negative regulation of stem cell proliferation, complement activation and retinoic acid metabolism (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Also notable was expression of many members of the complement pathway as well as many genes associated with retinoic acid metabolism (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). The relative gene set enrichment profiles highlight a potential further subcluster within the sc-distant cells which may indicate the presence of transitional cells at the interface between distant and proximal fibroblasts (<xref ref-type="fig" rid="fig4">Figure 4F</xref>).</p><p>Enrichments of transcription factor target gene sets (regulons) showed considerable divergence and reveals how spatially determined activity of transcription factors could underpin differential fibroblast programming.</p></sec><sec id="s2-4"><title>Podoplanin and hypoxia predict poor outcome whilst high level expression of immune regulatory genes associates with superior clinical outcome</title><p>The study cohort had been selected to comprise patients with poor or good clinical outcome to allow potential identification of spatial transcriptional correlates of disease progression. Poor outcome was defined as death within 1 year whilst patients with good outcome exhibited survival beyond 3 years (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Survival expression signatures within spatially defined regions of PDAC.</title><p>(<bold>A</bold>) Differential gene expression from all regions in relation to poor (&lt;1 year) or good (3+year) survival. Coloured points indicate differentially expressed genes (BH adjusted p&lt;0.05 and absolute log<sub>2</sub>FC &gt;0.25). (<bold>B</bold>) Regional expression of survival-associated genes identified in A. Mean +/-SE of mean. PS = Proximal Stroma; DS = Distant Stroma; I=Immune. (<bold>C</bold>) 3 yr/1 yr fold change in expression of survival-associated genes within Immune and Stroma regions. (BH adjusted p&lt;0.05 and absolute log<sub>2</sub>FC &gt;0.25). (<bold>D</bold>) 3 yr/1 yr fold change in expression of survival-associated genes within Tumor-Proximal and Tumor-Distal regions. (BH adjusted p&lt;0.05 and absolute log<sub>2</sub>FC &gt;0.25). (<bold>E</bold>) Venn displaying overlaps of 3 yr vs 1 yr survival DEGs (BH adjusted p&lt;0.05 and absolute log<sub>2</sub>FC &gt;0.25) within tumor-proximal stroma (PS), tumor-distal stroma (DS) and Immune (I) regions.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Profile of Survival expression signatures within PDAC TME.</title><p>(<bold>A</bold>) Average scRNA expression profile of Survival associated genes within high level cell types of scRNA-seq dataset (n=3). (<bold>B</bold>) Expression profile of Survival associated genes identified by 3 yr vs 1 yr differential expression analysis. (<bold>C</bold>) Proximal Stroma (PS): Distant Stroma (DS) ratios stratified by survival outcome for selected genes with significant difference in ratio when stratified by survival.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Overall gene expression profiles were initially compared between these two groups to define spatially unaware prognostic transcriptional signatures. High level transcriptional expression of <italic>PDPN, HIF1A, PDL1</italic> (CD274), and <italic>VEGFA</italic> were associated with poor clinical outcome (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Ten genes were upregulated in patients with survival beyond 3 years and were characterized predominantly by immune activation with increased expression of MHC class I and class II, complement C3 and chemokines CCL5 and CXCL9. The integrin ITGB2 (CD18) and STAT1 also showed increased expression in this group.</p><p>The spatial expression of these prognosis-associated genes was then assessed across the two risk groups (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). To further pinpoint the likely spatially-defined signal contribution of prognostic genes, good vs bad differentially expressed genes were identified from a within Immune region and within Stroma region analysis (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Additionally, within proximal and within distant stroma region analysis assessed the relative contribution to prognostic signals by proximity to tumor (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</p><p>Patients with a poor outcome expressed PDPN broadly across the tumor microenvironment whilst HIF-1α and VEGF expression also extended into the distal stromal and immune regions and likely indicates more extensive hypoxia in this subgroup. Proximal-to-distant stroma expression gradients could also be an indicator of prognosis with CD44, CCL5, EPCAM, and HIF1A all identified as having divergent gradients in Good vs Bad prognosis groups (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>).This further highlights the spreading of HIF1A as a feature of poor prognosis. Good prognosis was associated with broad expression of most immunostimulatory and immunoregulatory genes whilst expression of IL-11 and HLA-E was focused within distal stroma (<xref ref-type="fig" rid="fig5">Figure 5C, D and E</xref>). Expression of complement C3 and NKG7, a regulator of cytotoxic granule release (<xref ref-type="bibr" rid="bib33">Ng et al., 2020</xref>) within the immune region was also enhanced in patients with good clinical outcome.</p><p>A graphical summary (<xref ref-type="fig" rid="fig6">Figure 6</xref>) of the combined Nanostring nCounter and scRNA data analysis highlights these key data-defined characteristics of spatially determined regions within the PDAC tumor microenvironment.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Graphical summary of the transcriptional features of spatially defined regions in the PDAC tumor microenvironment.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86125-fig6-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Increased understanding of the pancreatic ductal adenocarcinoma microenvironment is essential for the development of targeted therapies. Here, we combined spatial and single cell transcriptomic analysis to interrogate patterns of cellular transcription in relation to tumor proximity and related this to clinical outcome. This reveals spatially determined transcriptional programming of fibroblasts with potential opportunities for therapeutic development.</p><p>Proximity to tumor was seen to be a strong determinant of transcriptional activity of stromal cells. In particular, DKK3 and PDPN were both increased markedly on tumor-proximal cells. PDPN expression is strongly enhanced on cancer-associated fibroblasts in PDAC (<xref ref-type="bibr" rid="bib46">Shindo et al., 2013</xref>) and high expression levels are correlated with poor prognosis in some, but not all, studies (<xref ref-type="bibr" rid="bib30">Mezawa and Orimo, 2016</xref>). DKK3 is a Wnt regulator and is emerging as a potentially important therapeutic target (<xref ref-type="bibr" rid="bib51">Zhou et al., 2018</xref>). A range of genes showed increased expression within stromal populations distal from tumor including the C3 component of complement and SFRP2, a soluble modulator of <ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/Wnt_signaling">Wnt signaling</ext-link>. CD34, a marker of stromal stem cells, was also expressed more highly in this region and may indicate spatial differentiation of stromal cells towards the tumor. Due to the nature of two-dimensional imaging, we cannot rule out that cancer cells may be present above or below the plane of the tissue section. Nonetheless, clear differences between stromal populations were observed suggesting that this potential occurrence did not significantly impact our analysis.</p><p>Integration of spatially defined transcription signatures with an additional single cell RNA-Seq dataset allowed development of a transcriptional atlas of proximal and distal stromal cells. Tumor-proximal populations displayed features typical of myofibroblasts whilst more distal populations had an inflammatory profile, in line with previous reports (<xref ref-type="bibr" rid="bib34">Öhlund et al., 2017</xref>). Myofibroblast markers included the potent pro-tumorigenic chemokine CXCL14 (<xref ref-type="bibr" rid="bib3">Augsten et al., 2014</xref>) and WNT5A which may contribute to the differentiation of adipocytes to CAFs (<xref ref-type="bibr" rid="bib53">Zoico et al., 2016</xref>). Indeed, Wnt ligand signaling plays a key role in PDAC progression and therapeutic resistance, and tumor-proximal fibroblasts are seen to be strong contributors to the Wnt ligand pool with high level expression of the ligands WNT5A, WNT11, WNT2, WNT5, WNT5A, and WNT5B. Transcriptional regulation of cell division was also increased, suggesting enhanced proliferation of stromal cells when locally exposed to tumor and in line with prior reports (<xref ref-type="bibr" rid="bib22">Kalluri and Zeisberg, 2006</xref>).</p><p>In contrast, stromal cells located more distally from tumor retained functions such as generation of extracellular matrix proteins. Striking expression of a wide range of complement proteins was also seen at this site. CAF populations expressing complement proteins have been observed previously in PDAC (<xref ref-type="bibr" rid="bib10">Chen et al., 2021a</xref>) and overlap with the transcriptional profile of inflammatory CAF. However, there remains debate as to their potential additional expression within myeloid lineages and high dimensional immunofluorescence analysis may help to resolve this. The physiological role of intracellular complement expression is receiving considerable interest with evidence that it may impact on immune surveillance in pre-clinical models (<xref ref-type="bibr" rid="bib26">Kwak et al., 2018</xref>). THY1 is not a canonical fibroblast marker but is typically expressed on subsets of myofibroblasts and here we also observed increased levels in the tumor-distal region. Interestingly, we find expression of inflammatory genes in some tumor distal α-SMA+ regions and it is tempting to speculate that this could represent a potential hybrid myofibroblastic/inflammatory CAF state.</p><p>A further finding of note was increased expression of a range of genes associated with retinoids. Vitamin A-containing lipid droplets are known to be enriched within quiescent pancreatic stellate cells in close proximity to the basal aspect of pancreatic acinar cells (<xref ref-type="bibr" rid="bib15">Erkan et al., 2012</xref>) and, as such, the increased retinoic acid signature in tumor-distal fibroblasts could indicate that these are less activated. Indeed, patients with PDAC are often vitamin A deficient whilst retinoic acid treatment can suppress stellate cell proliferation with associated reduction in Wnt-β-catenin signaling and localized tumor apoptosis (<xref ref-type="bibr" rid="bib18">Froeling et al., 2011</xref>). ATRA treatment has been shown to be tolerable in patients with advanced disease and is under investigation in phase I trials (<xref ref-type="bibr" rid="bib24">Kocher et al., 2020</xref>). Distal populations were also enriched for expression of genes associated with negative regulation of stem cell proliferation and may indicate a potential role for cells within this environment in limiting tumor cell progression.</p><p>CAF populations exhibit extreme plasticity and factors such as IL-1 and TGF-β are emerging as important mediators of local phenotype (<xref ref-type="bibr" rid="bib5">Biffi et al., 2019</xref>). Analysis of relative transcription factor binding expression within tumor-proximal or distal stroma identified substantial differences in transcription factor activity at the two sites. A wide range of transcription factor targets were differentially expressed and indicate the importance of local cellular environments in exploiting the transcriptional plasticity of fibroblasts.</p><p>The study cohort had been selected to include patients with poor or good clinical outcome, based on survival below 1 year or above 3 years, respectively. High level expression of podoplanin, HIF-1α and VEGF were associated with poor outcome. The negative prognostic impact of podoplanin expression in PDAC has been documented previously (<xref ref-type="bibr" rid="bib30">Mezawa and Orimo, 2016</xref>) and podoplanin-positive stromal cells enhance invasion and proliferation of tumor cells. However, downregulation of podoplanin expression does not reverse this effect indicating an important role for additional pathways within this population (<xref ref-type="bibr" rid="bib46">Shindo et al., 2013</xref>). PDAC disease progression following surgical resection is usually related to metastasis or local progression and the potential role of different fibroblast subsets in the development of the metastatic niche requires further investigation (<xref ref-type="bibr" rid="bib48">Xu et al., 2010</xref>).</p><p>Expression of HIF-1α is reflective of the hypoxic environment within PDAC tumors and indicates that the intensity of hypoxia is an independent determinant of clinical outcome (<xref ref-type="bibr" rid="bib49">Ye et al., 2014</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2021b</xref>; <xref ref-type="bibr" rid="bib19">Hao, 2015</xref>). Indeed, spatial extension of HIF-1α expression into distal stroma and immune microenvironments was an additional risk factor and indicates that the breadth of hypoxia is of prognostic importance. HIF-1α expression in PDAC is associated with a range of features including enrichment of glycolysis, modulation of mTORC1 and MYC signaling, and immune suppression (<xref ref-type="bibr" rid="bib52">Zhuang et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Zhao et al., 2014</xref>). As such, this represents a challenging tumor subgroup for therapeutic intervention, although the introduction of HIF-1α inhibitors offers encouragement in this regard (<xref ref-type="bibr" rid="bib44">Semenza, 2023</xref>). Hypoxia is also likely to explain increased levels of VEGF expression in patients with poor prognosis. VEGF-targeted therapies have not shown significant utility in PDAC but could potentially be considered as part of a multi-modal therapeutic approach (<xref ref-type="bibr" rid="bib8">Cabebe and Fisher, 2007</xref>).</p><p>In contrast, many immunoregulatory and immunostimulatory genes were increased in patients with good prognosis and concur with studies showing that the extent of lymphocytic infiltration is a favorable indicator for outcome. Liudahl et al. used chromogen-based multiplexed immunohistochemistry (mIHC) to generate an atlas of leucocyte contexture within PDAC (<xref ref-type="bibr" rid="bib27">Liudahl et al., 2021</xref>) and extended prognostic utility to immune subpopulations. It was noteworthy that elevated expression of HLA class II genes was seen in patients with longer term survival and as this association extended into stromal regions it may indicate an important role for HLA-DR +antigen-presenting CAF (ApCAF) populations (<xref ref-type="bibr" rid="bib13">Elyada et al., 2019</xref>). Expression of complement protein C3 was associated with good clinical outcome and indicates that this pathway can also help to contain tumor growth (<xref ref-type="bibr" rid="bib39">Revel et al., 2020</xref>) despite early indications of a potential pro-tumorigenic role (<xref ref-type="bibr" rid="bib26">Kwak et al., 2018</xref>). Indeed, the beneficial effect of ApCAF in lung cancer is mediated partially through expression of complement proteins which rescue intratumoral T cells from exhaustion (<xref ref-type="bibr" rid="bib23">Kerdidani et al., 2022</xref>) and this may provide a unifying explanation for the prognostic value of HLA class II and complement expression in this study.</p><p>Expression of IL-11 within distal stroma was also a positive prognostic sign and is noteworthy given a previous report of a similar association with elevated serum concentrations (<xref ref-type="bibr" rid="bib38">Ren et al., 2014</xref>). IL-11 is an inflammatory protein within the IL-6 family and as such further analysis of the mechanisms by which it can help to contain PDAC development would be valuable. High level expression of NKG7 within immune regions was also beneficial and, given its central role in regulation of cytotoxic granule release (<xref ref-type="bibr" rid="bib33">Ng et al., 2020</xref>), this is noteworthy given its emerging role as a predictive factor in response to checkpoint protein inhibition (<xref ref-type="bibr" rid="bib47">Wen et al., 2022</xref>). Overall, the transcriptional correlates of good prognosis clearly identify immunological processes as the central determinant of clinical outcome and augur well for therapeutic interventions that can unmask this immune potential. Immune checkpoint inhibition has been largely unsuccessful for this patient subgroup but there is clearly latent immunogenicity within the PDAC microenvironment and the use of agonistic anti-CD40 antibodies has shown promise in clinical studies (<xref ref-type="bibr" rid="bib7">Byrne et al., 2021</xref>).</p><p>A limitation of the study is that tumors are markedly heterogeneous and as such our findings may not be representative of the complete architecture. However, to overcome this we used a broad patient cohort and selected regions of interest from across the biopsies. Multiplex immunohistochemical analysis will also be of value to confirm co-expression of proteins within cell subsets.</p><p>In conclusion, we find that transcriptional activity of stromal subsets is strongly regulated by their relative proximity to tumor and define the transcriptional landscape in relation to spatial localization. Hypoxia is a correlate of poor outcome whilst approaches to enhance the inflammatory environment of distal stroma could offer strategies to improve the clinical outcome for this patient group. Indeed, successful therapy for PDAC may require multi-modal approaches such as HIF inhibition with immune checkpoint blockade (<xref ref-type="bibr" rid="bib43">Salman et al., 2022</xref>) or personalized vaccine regimens (<xref ref-type="bibr" rid="bib42">Rojas et al., 2023</xref>).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Participants</title><p>FFPE tissue from 25 treatment-naïve patients undergoing pylorus-preserving pancreatico-duodenectomy (PPPD) who presented with localized disease were selected for this study. Samples were obtained from the Birmingham Human Biomaterials Resource Centre HBRC (HTA Licence 12358) ethically approved North West - Haydock Research Ethics Committee; Ref 20/NW/0001, local ethics number 18–304.</p></sec><sec id="s4-2"><title>Sample processing</title><p>FFPE tissue blocks were sectioned at 5 μm thickness, deparaffinized and rehydrated using conventional methods. The slides were profiled using NanoString GeoMx Digital Spatial RNA Profiling (DSP) platform through the Technology Access Program (TAP) by NanoString (Seattle, WA, USA). Briefly, immunofluorescent antibody staining was performed with tissue morphology markers α-SMA, Syto83, Pan-CK ,and CD45 (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Morphology marker antibodies.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Name</th><th align="left" valign="bottom">Channel</th><th align="left" valign="bottom">Host</th><th align="left" valign="bottom">Company</th><th align="left" valign="bottom">Clone #</th><th align="left" valign="bottom">Catalog #</th><th align="left" valign="bottom">Concentration used</th></tr></thead><tbody><tr><td align="left" valign="bottom">SMA</td><td align="char" char="." valign="bottom">488</td><td align="left" valign="bottom">Mouse</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">1A4</td><td align="char" char="hyphen" valign="bottom">53-9760-82</td><td align="left" valign="bottom">1:200</td></tr><tr><td align="left" valign="bottom">Syto83</td><td align="char" char="." valign="bottom">532</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Thermo fisher</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">400 nM</td></tr><tr><td align="left" valign="bottom">PanCk</td><td align="char" char="." valign="bottom">594</td><td align="left" valign="bottom">Mouse</td><td align="left" valign="bottom">Novus</td><td align="left" valign="bottom">AE1/AE3</td><td align="left" valign="bottom">NBP2-33200DL594</td><td align="left" valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">CD45</td><td align="char" char="." valign="bottom">647</td><td align="left" valign="bottom">Mouse</td><td align="left" valign="bottom">Novus</td><td align="left" valign="bottom">2B11+PD7/26</td><td align="left" valign="bottom">NBP2-34528AF647</td><td align="left" valign="bottom">1:200</td></tr></tbody></table></table-wrap><p>In parallel, slides were stained with a panel of photocleavable RNA probes. Custom regions of interest (ROI) were selected based on these markers to generate specific domains including ‘tumor-proximal stroma’, tumor-distal stroma’ and ‘immune enriched’ areas. ‘Tumor-proximal stroma’ refers to regions within the tumor that are surrounded by tumor epithelium, while &quot;tumor-distal stroma&quot; refers to regions that are located as far away as possible from malignant ducts and lack surrounding epithelium.</p><p>To minimise the confounding effect of tumor heterogeneity, four ROI were selected for each domain per slide. UV-cleavable probes within each ROI were liberated by UV light, hybridized to optical fluorescent barcodes then counted on the nCounter to determine the absolute number of mRNA transcripts.</p></sec><sec id="s4-3"><title>NanoString nCounter data analysis</title><p>Raw NanoString nCounter data expression matrix (<xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>) was processed following the normalization and quality control procedures as described elsewhere (<xref ref-type="bibr" rid="bib4">Bhattacharya et al., 2021</xref>). Due to a redundancy in the tags used for both IFNG and ACTA2, data from these probes had to be removed from further analysis. Correlations of housekeeping gene expression across all ROIs were assessed to select the most correlated housekeeping probes H3F3A and UBB to use for downstream normalization (Supp. Figure S2A). Unwanted variation was removed using the R package RUVSeq (<xref ref-type="bibr" rid="bib40">Risso et al., 2014</xref>). Firstly, distributional differences were scaled between lanes using upper-quartile normalization then unwanted technical factors were estimated in the resulting gene expression data with the RUVg function selecting H3F3A and UBB as the negative control genes and the number of dimensions of unwanted variation to remove set to 1. A variance stabilizing transformation of the original count data was computed using DESeq2 (<xref ref-type="bibr" rid="bib28">Love et al., 2014</xref>) and estimated unwanted variation was removed using the removeBatchEffects function from limma (<xref ref-type="bibr" rid="bib41">Ritchie et al., 2015</xref>). RLE plots were used to detect any potential outliers before and after normalization (Supp. Figure S2B).</p><p>Differential expression analysis was conducted to compare Immune vs stromal regions, 3 yr vs 1 yr survival and tumor-proximal vs tumor-distant stromal regions using DESeq2, adjusting for multiple testing with Benjamini-Hochberg (BH) procedure. Differentially expressed genes were determined by BH adjusted p&lt;0.05 and absolute log2FC &gt;0.25.</p><p>Dimensionality reduction by Uniform Manifold Approximation and Projection (UMAP) was performed on the normalized counts matrix with the umap R package and ggplot2 utilized for plotting. Heatmap visualizations were generated using the ComplexHeatmap package. Pearson correlation was calculated and plots generated using ggpairs and ggcorr functions from the R package GGally.</p></sec><sec id="s4-4"><title>scRNA-Seq data analysis</title><p>Genes of interest identified from nCounter data analysis were further explored for their expression profiles in single-cell RNA sequencing data (GEO accession GSE210199) of cells within the tumor microenvironment of 3 PDAC patients (<xref ref-type="bibr" rid="bib36">Pearce et al., 2023</xref>).</p></sec><sec id="s4-5"><title>Raw read data processing</title><p>Raw reads were processed using CellRanger (10X Genomics, v3) functions mkfastq and count. Raw bcl files were converted to fastq and aligned to the human reference genome GRCh38. Gene expression matrices for each patient were analyzed by R software (v3.6). Data pre-processing, QC, dimensionality reduction, clustering and subsequent downstream analysis was performed using the Seurat package (v3.1.1).</p></sec><sec id="s4-6"><title>Data integration and clustering</title><p>Data from 3 PDAC patient samples was integrated following Seurat SCTransform Integrate Data workflow using the top 3000 most variable genes as integration features. Principal Component Analysis (PCA) was applied and Uniform Manifold Approximation and Projection (UMAP) embedding determined using PCs 1:20. For unsupervised clustering, a shared nearest neighbour graph based on Euclidean distance in PCA space was constructed using Seurat FindNeighbours function and the modules within this graph representing clusters were identified using the Louvain algorithm with Seurat FindClusters.</p><p>To annotate clusters with high-level cell type, canonical cell type marker gene expression level was assessed.</p></sec><sec id="s4-7"><title>scRNA-Seq Fibroblast data analysis</title><p>Transcriptome data was subset taking Fibroblast cells only and unsupervised clustering re-applied on Fibroblasts alone. Expression profile of stromal expressed genes identified from the nCounter dataset to be associated with tumor proximal or tumor-distant regions was assessed within the Fibroblast scRNA-Seq data. These tumor-proximal and tumor-distant gene signatures were scored using GSVA to assess likely tumor-proximal and tumor-distant fibroblasts. Expression profiling and GSVA signature scoring were used to annotate fibroblast subpopulations identified through clustering as ‘Proximal-like’ and ‘Distant-like’.</p><p>To expand the pool of possible transcriptional markers for tumor proximal and tumor distant fibroblasts, differential expression analysis was conducted comparing Proximal-like and Distant-like clusters using findMarkers with MAST option (test.use = ‘MAST’), which uses a hurdle model tailored to scRNA-Seq data. MAST is a two-part GLM that simultaneously models how many cells express the gene by logistic regression and the expression level by Gaussian distribution (<xref ref-type="bibr" rid="bib17">Finak et al., 2015</xref>). Differential expression testing was performed using the likelihood ratio test. Differentially expressed genes were determined by Benjamini Hochberg adjusted p&lt;0.05 and absolute log2FC &gt;0.5.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Supervision, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Supervision, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Funding acquisition, Writing - review and editing</p></fn><fn fn-type="con" id="con15"><p>Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Supervision, Funding acquisition, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Samples were obtained from the Birmingham Human Biomaterials Resource Centre HBRC (HTA Licence 12358) ethically approved North West - Haydock Research Ethics Committee; Ref 20/NW/0001, local ethics number 18-304.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>NanoString nCounter RNA hybridisation probeset.</title><p>List of RNA probe panels used for Nanostring nCounter data collection including the immunoncology core panel, fibroblast-specific, housekeeping and negative control probe sets.</p></caption><media xlink:href="elife-86125-supp1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-86125-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Raw NanoString nCounter data.</title></caption><media xlink:href="elife-86125-data1-v2.csv" mimetype="application" mime-subtype="octet-stream"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p><xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref> contains the raw Nanostring nCounter data.</p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>H</given-names></name><name><surname>Croft</surname><given-names>W</given-names></name><name><surname>Nicol</surname><given-names>S</given-names></name><name><surname>Margielewska-Davies</surname><given-names>S</given-names></name><name><surname>Powell</surname><given-names>R</given-names></name><name><surname>Cornall</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>SJ</given-names></name><name><surname>Marcon</surname><given-names>F</given-names></name><name><surname>Pugh</surname><given-names>M</given-names></name><name><surname>Powell-Brett</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Middleton</surname><given-names>G</given-names></name><name><surname>Mahon</surname><given-names>B</given-names></name><name><surname>Fennell</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Tissue-resident memory T-cells in pancreatic ductal adenocarcinoma co-express PD-1 and TIGIT and inhibition is reversible by dual antibody blockade</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE210199">GSE210199</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This research was supported by a Cancer Research UK (CRUK) Programme Grant CRUK-A21135.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albrengues</surname><given-names>J</given-names></name><name><surname>Meneguzzi</surname><given-names>G</given-names></name><name><surname>Gaggioli</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Carcinoma-associated fibroblasts in cancer: the great escape</article-title><source>Medecine Sciences</source><volume>30</volume><fpage>391</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1051/medsci/20143004012</pub-id><pub-id pub-id-type="pmid">24801033</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>M</given-names></name><name><surname>Rutherford</surname><given-names>MJ</given-names></name><name><surname>Bardot</surname><given-names>A</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>TM-L</given-names></name><name><surname>Myklebust</surname><given-names>TÅ</given-names></name><name><surname>Tervonen</surname><given-names>H</given-names></name><name><surname>Thursfield</surname><given-names>V</given-names></name><name><surname>Ransom</surname><given-names>D</given-names></name><name><surname>Shack</surname><given-names>L</given-names></name><name><surname>Woods</surname><given-names>RR</given-names></name><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Leonfellner</surname><given-names>S</given-names></name><name><surname>Ryan</surname><given-names>S</given-names></name><name><surname>Saint-Jacques</surname><given-names>N</given-names></name><name><surname>De</surname><given-names>P</given-names></name><name><surname>McClure</surname><given-names>C</given-names></name><name><surname>Ramanakumar</surname><given-names>AV</given-names></name><name><surname>Stuart-Panko</surname><given-names>H</given-names></name><name><surname>Engholm</surname><given-names>G</given-names></name><name><surname>Walsh</surname><given-names>PM</given-names></name><name><surname>Jackson</surname><given-names>C</given-names></name><name><surname>Vernon</surname><given-names>S</given-names></name><name><surname>Morgan</surname><given-names>E</given-names></name><name><surname>Gavin</surname><given-names>A</given-names></name><name><surname>Morrison</surname><given-names>DS</given-names></name><name><surname>Huws</surname><given-names>DW</given-names></name><name><surname>Porter</surname><given-names>G</given-names></name><name><surname>Butler</surname><given-names>J</given-names></name><name><surname>Bryant</surname><given-names>H</given-names></name><name><surname>Currow</surname><given-names>DC</given-names></name><name><surname>Hiom</surname><given-names>S</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Sasieni</surname><given-names>P</given-names></name><name><surname>Lambert</surname><given-names>PC</given-names></name><name><surname>Møller</surname><given-names>B</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study</article-title><source>The Lancet. Oncology</source><volume>20</volume><fpage>1493</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30456-5</pub-id><pub-id pub-id-type="pmid">31521509</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augsten</surname><given-names>M</given-names></name><name><surname>Sjöberg</surname><given-names>E</given-names></name><name><surname>Frings</surname><given-names>O</given-names></name><name><surname>Vorrink</surname><given-names>SU</given-names></name><name><surname>Frijhoff</surname><given-names>J</given-names></name><name><surname>Olsson</surname><given-names>E</given-names></name><name><surname>Borg</surname><given-names>Å</given-names></name><name><surname>Östman</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties</article-title><source>Cancer Research</source><volume>74</volume><fpage>2999</fpage><lpage>3010</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2740</pub-id><pub-id pub-id-type="pmid">24710408</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>A</given-names></name><name><surname>Hamilton</surname><given-names>AM</given-names></name><name><surname>Furberg</surname><given-names>H</given-names></name><name><surname>Pietzak</surname><given-names>E</given-names></name><name><surname>Purdue</surname><given-names>MP</given-names></name><name><surname>Troester</surname><given-names>MA</given-names></name><name><surname>Hoadley</surname><given-names>KA</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>An approach for normalization and quality control for nanostring RNA expression data</article-title><source>Briefings in Bioinformatics</source><volume>22</volume><elocation-id>bbaa163</elocation-id><pub-id pub-id-type="doi">10.1093/bib/bbaa163</pub-id><pub-id pub-id-type="pmid">32789507</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biffi</surname><given-names>G</given-names></name><name><surname>Oni</surname><given-names>TE</given-names></name><name><surname>Spielman</surname><given-names>B</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Elyada</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Preall</surname><given-names>J</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma</article-title><source>Cancer Discovery</source><volume>9</volume><fpage>282</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-0710</pub-id><pub-id pub-id-type="pmid">30366930</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biffi</surname><given-names>G</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Diversity and biology of cancer-associated fibroblasts</article-title><source>Physiological Reviews</source><volume>101</volume><fpage>147</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1152/physrev.00048.2019</pub-id><pub-id pub-id-type="pmid">32466724</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrne</surname><given-names>KT</given-names></name><name><surname>Betts</surname><given-names>CB</given-names></name><name><surname>Mick</surname><given-names>R</given-names></name><name><surname>Sivagnanam</surname><given-names>S</given-names></name><name><surname>Bajor</surname><given-names>DL</given-names></name><name><surname>Laheru</surname><given-names>DA</given-names></name><name><surname>Chiorean</surname><given-names>EG</given-names></name><name><surname>O’Hara</surname><given-names>MH</given-names></name><name><surname>Liudahl</surname><given-names>SM</given-names></name><name><surname>Newcomb</surname><given-names>C</given-names></name><name><surname>Alanio</surname><given-names>C</given-names></name><name><surname>Ferreira</surname><given-names>AP</given-names></name><name><surname>Park</surname><given-names>BS</given-names></name><name><surname>Ohtani</surname><given-names>T</given-names></name><name><surname>Huffman</surname><given-names>AP</given-names></name><name><surname>Väyrynen</surname><given-names>SA</given-names></name><name><surname>Dias Costa</surname><given-names>A</given-names></name><name><surname>Kaiser</surname><given-names>JC</given-names></name><name><surname>Lacroix</surname><given-names>AM</given-names></name><name><surname>Redlinger</surname><given-names>C</given-names></name><name><surname>Stern</surname><given-names>M</given-names></name><name><surname>Nowak</surname><given-names>JA</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><name><surname>Cheever</surname><given-names>MA</given-names></name><name><surname>Wolpin</surname><given-names>BM</given-names></name><name><surname>Furth</surname><given-names>EE</given-names></name><name><surname>Jaffee</surname><given-names>EM</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Vonderheide</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Neoadjuvant selicrelumab, an agonist Cd40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer</article-title><source>Clinical Cancer Research</source><volume>27</volume><fpage>4574</fpage><lpage>4586</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-1047</pub-id><pub-id pub-id-type="pmid">34112709</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabebe</surname><given-names>E</given-names></name><name><surname>Fisher</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Clinical trials of VEGF receptor tyrosine kinase inhibitors in Pancreatic cancer</article-title><source>Expert Opinion on Investigational Drugs</source><volume>16</volume><fpage>467</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1517/13543784.16.4.467</pub-id><pub-id pub-id-type="pmid">17371195</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catenacci</surname><given-names>DVT</given-names></name><name><surname>Junttila</surname><given-names>MR</given-names></name><name><surname>Karrison</surname><given-names>T</given-names></name><name><surname>Bahary</surname><given-names>N</given-names></name><name><surname>Horiba</surname><given-names>MN</given-names></name><name><surname>Nattam</surname><given-names>SR</given-names></name><name><surname>Marsh</surname><given-names>R</given-names></name><name><surname>Wallace</surname><given-names>J</given-names></name><name><surname>Kozloff</surname><given-names>M</given-names></name><name><surname>Rajdev</surname><given-names>L</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Wade</surname><given-names>J</given-names></name><name><surname>Sleckman</surname><given-names>B</given-names></name><name><surname>Lenz</surname><given-names>H-J</given-names></name><name><surname>Stiff</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Henderson</surname><given-names>L</given-names></name><name><surname>Takebe</surname><given-names>N</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><name><surname>de Sauvage</surname><given-names>FJ</given-names></name><name><surname>Kindler</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Randomized phase IB/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer</article-title><source>Journal of Clinical Oncology</source><volume>33</volume><fpage>4284</fpage><lpage>4292</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.62.8719</pub-id><pub-id pub-id-type="pmid">26527777</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression</article-title><source>EBioMedicine</source><volume>66</volume><elocation-id>103315</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103315</pub-id><pub-id pub-id-type="pmid">33819739</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Development and verification of the hypoxia- and immune-associated prognostic signature for pancreatic ductal adenocarcinoma</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>728062</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.728062</pub-id><pub-id pub-id-type="pmid">34691034</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez</surname><given-names>CX</given-names></name><name><surname>Müller</surname><given-names>S</given-names></name><name><surname>Keerthivasan</surname><given-names>S</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name><name><surname>Hung</surname><given-names>J</given-names></name><name><surname>Gierke</surname><given-names>S</given-names></name><name><surname>Breart</surname><given-names>B</given-names></name><name><surname>Foreman</surname><given-names>O</given-names></name><name><surname>Bainbridge</surname><given-names>TW</given-names></name><name><surname>Castiglioni</surname><given-names>A</given-names></name><name><surname>Senbabaoglu</surname><given-names>Y</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Junttila</surname><given-names>MR</given-names></name><name><surname>Klijn</surname><given-names>C</given-names></name><name><surname>Bourgon</surname><given-names>R</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy</article-title><source>Cancer Discovery</source><volume>10</volume><fpage>232</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-0644</pub-id><pub-id pub-id-type="pmid">31699795</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elyada</surname><given-names>E</given-names></name><name><surname>Bolisetty</surname><given-names>M</given-names></name><name><surname>Laise</surname><given-names>P</given-names></name><name><surname>Flynn</surname><given-names>WF</given-names></name><name><surname>Courtois</surname><given-names>ET</given-names></name><name><surname>Burkhart</surname><given-names>RA</given-names></name><name><surname>Teinor</surname><given-names>JA</given-names></name><name><surname>Belleau</surname><given-names>P</given-names></name><name><surname>Biffi</surname><given-names>G</given-names></name><name><surname>Lucito</surname><given-names>MS</given-names></name><name><surname>Sivajothi</surname><given-names>S</given-names></name><name><surname>Armstrong</surname><given-names>TD</given-names></name><name><surname>Engle</surname><given-names>DD</given-names></name><name><surname>Yu</surname><given-names>KH</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Wolfgang</surname><given-names>CL</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Preall</surname><given-names>J</given-names></name><name><surname>Jaffee</surname><given-names>EM</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name><name><surname>Robson</surname><given-names>P</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts</article-title><source>Cancer Discovery</source><volume>9</volume><fpage>1102</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-0094</pub-id><pub-id pub-id-type="pmid">31197017</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ene-Obong</surname><given-names>A</given-names></name><name><surname>Clear</surname><given-names>AJ</given-names></name><name><surname>Watt</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fatah</surname><given-names>R</given-names></name><name><surname>Riches</surname><given-names>JC</given-names></name><name><surname>Marshall</surname><given-names>JF</given-names></name><name><surname>Chin-Aleong</surname><given-names>J</given-names></name><name><surname>Chelala</surname><given-names>C</given-names></name><name><surname>Gribben</surname><given-names>JG</given-names></name><name><surname>Ramsay</surname><given-names>AG</given-names></name><name><surname>Kocher</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma</article-title><source>Gastroenterology</source><volume>145</volume><fpage>1121</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2013.07.025</pub-id><pub-id pub-id-type="pmid">23891972</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erkan</surname><given-names>M</given-names></name><name><surname>Adler</surname><given-names>G</given-names></name><name><surname>Apte</surname><given-names>MV</given-names></name><name><surname>Bachem</surname><given-names>MG</given-names></name><name><surname>Buchholz</surname><given-names>M</given-names></name><name><surname>Detlefsen</surname><given-names>S</given-names></name><name><surname>Esposito</surname><given-names>I</given-names></name><name><surname>Friess</surname><given-names>H</given-names></name><name><surname>Gress</surname><given-names>TM</given-names></name><name><surname>Habisch</surname><given-names>HJ</given-names></name><name><surname>Hwang</surname><given-names>RF</given-names></name><name><surname>Jaster</surname><given-names>R</given-names></name><name><surname>Kleeff</surname><given-names>J</given-names></name><name><surname>Klöppel</surname><given-names>G</given-names></name><name><surname>Kordes</surname><given-names>C</given-names></name><name><surname>Logsdon</surname><given-names>CD</given-names></name><name><surname>Masamune</surname><given-names>A</given-names></name><name><surname>Michalski</surname><given-names>CW</given-names></name><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Phillips</surname><given-names>PA</given-names></name><name><surname>Pinzani</surname><given-names>M</given-names></name><name><surname>Reiser-Erkan</surname><given-names>C</given-names></name><name><surname>Tsukamoto</surname><given-names>H</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>StellaTUM: current consensus and discussion on pancreatic stellate cell research</article-title><source>Gut</source><volume>61</volume><fpage>172</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2011-301220</pub-id><pub-id pub-id-type="pmid">22115911</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Rong</surname><given-names>Y</given-names></name><name><surname>Kuang</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Lou</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer</article-title><source>Experimental Cell Research</source><volume>383</volume><elocation-id>111543</elocation-id><pub-id pub-id-type="doi">10.1016/j.yexcr.2019.111543</pub-id><pub-id pub-id-type="pmid">31374207</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finak</surname><given-names>G</given-names></name><name><surname>McDavid</surname><given-names>A</given-names></name><name><surname>Yajima</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Gersuk</surname><given-names>V</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Slichter</surname><given-names>CK</given-names></name><name><surname>Miller</surname><given-names>HW</given-names></name><name><surname>McElrath</surname><given-names>MJ</given-names></name><name><surname>Prlic</surname><given-names>M</given-names></name><name><surname>Linsley</surname><given-names>PS</given-names></name><name><surname>Gottardo</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data</article-title><source>Genome Biology</source><volume>16</volume><elocation-id>278</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-015-0844-5</pub-id><pub-id pub-id-type="pmid">26653891</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froeling</surname><given-names>FEM</given-names></name><name><surname>Feig</surname><given-names>C</given-names></name><name><surname>Chelala</surname><given-names>C</given-names></name><name><surname>Dobson</surname><given-names>R</given-names></name><name><surname>Mein</surname><given-names>CE</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Hart</surname><given-names>IR</given-names></name><name><surname>Kocher</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression</article-title><source>Gastroenterology</source><volume>141</volume><fpage>1486</fpage><lpage>1497</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.06.047</pub-id><pub-id pub-id-type="pmid">21704588</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HIF-1 is a critical target of pancreatic cancer</article-title><source>Oncoimmunology</source><volume>4</volume><elocation-id>e1026535</elocation-id><pub-id pub-id-type="doi">10.1080/2162402X.2015.1026535</pub-id><pub-id pub-id-type="pmid">26405594</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirayama</surname><given-names>K</given-names></name><name><surname>Kono</surname><given-names>H</given-names></name><name><surname>Nakata</surname><given-names>Y</given-names></name><name><surname>Akazawa</surname><given-names>Y</given-names></name><name><surname>Wakana</surname><given-names>H</given-names></name><name><surname>Fukushima</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Expression of podoplanin in stromal fibroblasts plays a pivotal role in the prognosis of patients with pancreatic cancer</article-title><source>Surgery Today</source><volume>48</volume><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1007/s00595-017-1559-x</pub-id><pub-id pub-id-type="pmid">28702871</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Adachi</surname><given-names>K</given-names></name><name><surname>Kawana</surname><given-names>K</given-names></name><name><surname>Taguchi</surname><given-names>A</given-names></name><name><surname>Nagamatsu</surname><given-names>T</given-names></name><name><surname>Fujimoto</surname><given-names>A</given-names></name><name><surname>Tomio</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>A</given-names></name><name><surname>Eguchi</surname><given-names>S</given-names></name><name><surname>Nishida</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Arimoto</surname><given-names>T</given-names></name><name><surname>Wada-Hiraike</surname><given-names>O</given-names></name><name><surname>Oda</surname><given-names>K</given-names></name><name><surname>Osuga</surname><given-names>Y</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of activating NK receptor</article-title><source>International Journal of Oncology</source><volume>49</volume><fpage>1297</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.3892/ijo.2016.3631</pub-id><pub-id pub-id-type="pmid">27499237</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalluri</surname><given-names>R</given-names></name><name><surname>Zeisberg</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Fibroblasts in cancer</article-title><source>Nature Reviews. Cancer</source><volume>6</volume><fpage>392</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/nrc1877</pub-id><pub-id pub-id-type="pmid">16572188</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerdidani</surname><given-names>D</given-names></name><name><surname>Aerakis</surname><given-names>E</given-names></name><name><surname>Verrou</surname><given-names>K-M</given-names></name><name><surname>Angelidis</surname><given-names>I</given-names></name><name><surname>Douka</surname><given-names>K</given-names></name><name><surname>Maniou</surname><given-names>M-A</given-names></name><name><surname>Stamoulis</surname><given-names>P</given-names></name><name><surname>Goudevenou</surname><given-names>K</given-names></name><name><surname>Prados</surname><given-names>A</given-names></name><name><surname>Tzaferis</surname><given-names>C</given-names></name><name><surname>Ntafis</surname><given-names>V</given-names></name><name><surname>Vamvakaris</surname><given-names>I</given-names></name><name><surname>Kaniaris</surname><given-names>E</given-names></name><name><surname>Vachlas</surname><given-names>K</given-names></name><name><surname>Sepsas</surname><given-names>E</given-names></name><name><surname>Koutsopoulos</surname><given-names>A</given-names></name><name><surname>Potaris</surname><given-names>K</given-names></name><name><surname>Tsoumakidou</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts</article-title><source>The Journal of Experimental Medicine</source><volume>219</volume><elocation-id>e20210815</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20210815</pub-id><pub-id pub-id-type="pmid">35029648</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kocher</surname><given-names>HM</given-names></name><name><surname>Basu</surname><given-names>B</given-names></name><name><surname>Froeling</surname><given-names>FEM</given-names></name><name><surname>Sarker</surname><given-names>D</given-names></name><name><surname>Slater</surname><given-names>S</given-names></name><name><surname>Carlin</surname><given-names>D</given-names></name><name><surname>deSouza</surname><given-names>NM</given-names></name><name><surname>De Paepe</surname><given-names>KN</given-names></name><name><surname>Goulart</surname><given-names>MR</given-names></name><name><surname>Hughes</surname><given-names>C</given-names></name><name><surname>Imrali</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Pawula</surname><given-names>M</given-names></name><name><surname>Houghton</surname><given-names>R</given-names></name><name><surname>Lawrence</surname><given-names>C</given-names></name><name><surname>Yogeswaran</surname><given-names>Y</given-names></name><name><surname>Mousa</surname><given-names>K</given-names></name><name><surname>Coetzee</surname><given-names>C</given-names></name><name><surname>Sasieni</surname><given-names>P</given-names></name><name><surname>Prendergast</surname><given-names>A</given-names></name><name><surname>Propper</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4841</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-18636-w</pub-id><pub-id pub-id-type="pmid">32973176</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Donthireddy</surname><given-names>L</given-names></name><name><surname>Marvel</surname><given-names>D</given-names></name><name><surname>Condamine</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Lavilla-Alonso</surname><given-names>S</given-names></name><name><surname>Hashimoto</surname><given-names>A</given-names></name><name><surname>Vonteddu</surname><given-names>P</given-names></name><name><surname>Behera</surname><given-names>R</given-names></name><name><surname>Goins</surname><given-names>MA</given-names></name><name><surname>Mulligan</surname><given-names>C</given-names></name><name><surname>Nam</surname><given-names>B</given-names></name><name><surname>Hockstein</surname><given-names>N</given-names></name><name><surname>Denstman</surname><given-names>F</given-names></name><name><surname>Shakamuri</surname><given-names>S</given-names></name><name><surname>Speicher</surname><given-names>DW</given-names></name><name><surname>Weeraratna</surname><given-names>AT</given-names></name><name><surname>Chao</surname><given-names>T</given-names></name><name><surname>Vonderheide</surname><given-names>RH</given-names></name><name><surname>Languino</surname><given-names>LR</given-names></name><name><surname>Ordentlich</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Lo</surname><given-names>A</given-names></name><name><surname>Puré</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Loboda</surname><given-names>A</given-names></name><name><surname>Sepulveda</surname><given-names>MA</given-names></name><name><surname>Snyder</surname><given-names>LA</given-names></name><name><surname>Gabrilovich</surname><given-names>DI</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cancer-associated fibroblasts neutralize the anti-tumor effect of Csf1 receptor blockade by inducing PMN-MDSC infiltration of tumors</article-title><source>Cancer Cell</source><volume>32</volume><fpage>654</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.10.005</pub-id><pub-id pub-id-type="pmid">29136508</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>JW</given-names></name><name><surname>Laskowski</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>HY</given-names></name><name><surname>McSharry</surname><given-names>MV</given-names></name><name><surname>Sippel</surname><given-names>TR</given-names></name><name><surname>Bullock</surname><given-names>BL</given-names></name><name><surname>Johnson</surname><given-names>AM</given-names></name><name><surname>Poczobutt</surname><given-names>JM</given-names></name><name><surname>Neuwelt</surname><given-names>AJ</given-names></name><name><surname>Malkoski</surname><given-names>SP</given-names></name><name><surname>Weiser-Evans</surname><given-names>MC</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name><name><surname>Clambey</surname><given-names>ET</given-names></name><name><surname>Thurman</surname><given-names>JM</given-names></name><name><surname>Nemenoff</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Complement activation via a C3A receptor pathway alters Cd4(+) T lymphocytes and mediates lung cancer progression</article-title><source>Cancer Research</source><volume>78</volume><fpage>143</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0240</pub-id><pub-id pub-id-type="pmid">29118090</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liudahl</surname><given-names>SM</given-names></name><name><surname>Betts</surname><given-names>CB</given-names></name><name><surname>Sivagnanam</surname><given-names>S</given-names></name><name><surname>Morales-Oyarvide</surname><given-names>V</given-names></name><name><surname>da Silva</surname><given-names>A</given-names></name><name><surname>Yuan</surname><given-names>C</given-names></name><name><surname>Hwang</surname><given-names>S</given-names></name><name><surname>Grossblatt-Wait</surname><given-names>A</given-names></name><name><surname>Leis</surname><given-names>KR</given-names></name><name><surname>Larson</surname><given-names>W</given-names></name><name><surname>Lavoie</surname><given-names>MB</given-names></name><name><surname>Robinson</surname><given-names>P</given-names></name><name><surname>Dias Costa</surname><given-names>A</given-names></name><name><surname>Väyrynen</surname><given-names>SA</given-names></name><name><surname>Clancy</surname><given-names>TE</given-names></name><name><surname>Rubinson</surname><given-names>DA</given-names></name><name><surname>Link</surname><given-names>J</given-names></name><name><surname>Keith</surname><given-names>D</given-names></name><name><surname>Horton</surname><given-names>W</given-names></name><name><surname>Tempero</surname><given-names>MA</given-names></name><name><surname>Vonderheide</surname><given-names>RH</given-names></name><name><surname>Jaffee</surname><given-names>EM</given-names></name><name><surname>Sheppard</surname><given-names>B</given-names></name><name><surname>Goecks</surname><given-names>J</given-names></name><name><surname>Sears</surname><given-names>RC</given-names></name><name><surname>Park</surname><given-names>BS</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Nowak</surname><given-names>JA</given-names></name><name><surname>Wolpin</surname><given-names>BM</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: Phenotypic and spatial features associated with clinical outcome</article-title><source>Cancer Discovery</source><volume>11</volume><fpage>2014</fpage><lpage>2031</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0841</pub-id><pub-id pub-id-type="pmid">33727309</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menezes</surname><given-names>S</given-names></name><name><surname>Okail</surname><given-names>MH</given-names></name><name><surname>Jalil</surname><given-names>SMA</given-names></name><name><surname>Kocher</surname><given-names>HM</given-names></name><name><surname>Cameron</surname><given-names>AJM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets</article-title><source>The Journal of Pathology</source><volume>257</volume><fpage>526</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1002/path.5926</pub-id><pub-id pub-id-type="pmid">35533046</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mezawa</surname><given-names>Y</given-names></name><name><surname>Orimo</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas</article-title><source>Cell and Tissue Research</source><volume>365</volume><fpage>675</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1007/s00441-016-2471-1</pub-id><pub-id pub-id-type="pmid">27506216</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mhaidly</surname><given-names>R</given-names></name><name><surname>Mechta-Grigoriou</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer</article-title><source>Immunological Reviews</source><volume>302</volume><fpage>259</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1111/imr.12978</pub-id><pub-id pub-id-type="pmid">34013544</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuzillet</surname><given-names>C</given-names></name><name><surname>Tijeras-Raballand</surname><given-names>A</given-names></name><name><surname>Ragulan</surname><given-names>C</given-names></name><name><surname>Cros</surname><given-names>J</given-names></name><name><surname>Patil</surname><given-names>Y</given-names></name><name><surname>Martinet</surname><given-names>M</given-names></name><name><surname>Erkan</surname><given-names>M</given-names></name><name><surname>Kleeff</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name><name><surname>Apte</surname><given-names>M</given-names></name><name><surname>Tosolini</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>AS</given-names></name><name><surname>Delvecchio</surname><given-names>FR</given-names></name><name><surname>Bousquet</surname><given-names>C</given-names></name><name><surname>Paradis</surname><given-names>V</given-names></name><name><surname>Hammel</surname><given-names>P</given-names></name><name><surname>Sadanandam</surname><given-names>A</given-names></name><name><surname>Kocher</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma</article-title><source>The Journal of Pathology</source><volume>248</volume><fpage>51</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1002/path.5224</pub-id><pub-id pub-id-type="pmid">30575030</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>SS</given-names></name><name><surname>De Labastida Rivera</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Corvino</surname><given-names>D</given-names></name><name><surname>Das</surname><given-names>I</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Kuns</surname><given-names>R</given-names></name><name><surname>Chauhan</surname><given-names>SB</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Frame</surname><given-names>TCM</given-names></name><name><surname>McEnroe</surname><given-names>BA</given-names></name><name><surname>Moore</surname><given-names>E</given-names></name><name><surname>Na</surname><given-names>J</given-names></name><name><surname>Engel</surname><given-names>JA</given-names></name><name><surname>Soon</surname><given-names>MSF</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Kueh</surname><given-names>AJ</given-names></name><name><surname>Herold</surname><given-names>MJ</given-names></name><name><surname>Montes de Oca</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>SS</given-names></name><name><surname>Bunn</surname><given-names>PT</given-names></name><name><surname>Aguilera</surname><given-names>AR</given-names></name><name><surname>Casey</surname><given-names>M</given-names></name><name><surname>Braun</surname><given-names>M</given-names></name><name><surname>Ghazanfari</surname><given-names>N</given-names></name><name><surname>Wani</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Amante</surname><given-names>FH</given-names></name><name><surname>Edwards</surname><given-names>CL</given-names></name><name><surname>Haque</surname><given-names>A</given-names></name><name><surname>Dougall</surname><given-names>WC</given-names></name><name><surname>Singh</surname><given-names>OP</given-names></name><name><surname>Baxter</surname><given-names>AG</given-names></name><name><surname>Teng</surname><given-names>MWL</given-names></name><name><surname>Loukas</surname><given-names>A</given-names></name><name><surname>Daly</surname><given-names>NL</given-names></name><name><surname>Cloonan</surname><given-names>N</given-names></name><name><surname>Degli-Esposti</surname><given-names>MA</given-names></name><name><surname>Uzonna</surname><given-names>J</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name><name><surname>Bald</surname><given-names>T</given-names></name><name><surname>Tey</surname><given-names>SK</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Hill</surname><given-names>GR</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Sundar</surname><given-names>S</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Engwerda</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation</article-title><source>Nature Immunology</source><volume>21</volume><fpage>1205</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0758-6</pub-id><pub-id pub-id-type="pmid">32839608</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Öhlund</surname><given-names>D</given-names></name><name><surname>Handly-Santana</surname><given-names>A</given-names></name><name><surname>Biffi</surname><given-names>G</given-names></name><name><surname>Elyada</surname><given-names>E</given-names></name><name><surname>Almeida</surname><given-names>AS</given-names></name><name><surname>Ponz-Sarvise</surname><given-names>M</given-names></name><name><surname>Corbo</surname><given-names>V</given-names></name><name><surname>Oni</surname><given-names>TE</given-names></name><name><surname>Hearn</surname><given-names>SA</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Chio</surname><given-names>IIC</given-names></name><name><surname>Hwang</surname><given-names>C-I</given-names></name><name><surname>Tiriac</surname><given-names>H</given-names></name><name><surname>Baker</surname><given-names>LA</given-names></name><name><surname>Engle</surname><given-names>DD</given-names></name><name><surname>Feig</surname><given-names>C</given-names></name><name><surname>Kultti</surname><given-names>A</given-names></name><name><surname>Egeblad</surname><given-names>M</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name><name><surname>Crawford</surname><given-names>JM</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer</article-title><source>The Journal of Experimental Medicine</source><volume>214</volume><fpage>579</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1084/jem.20162024</pub-id><pub-id pub-id-type="pmid">28232471</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Özdemir</surname><given-names>BC</given-names></name><name><surname>Pentcheva-Hoang</surname><given-names>T</given-names></name><name><surname>Carstens</surname><given-names>JL</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>C-C</given-names></name><name><surname>Simpson</surname><given-names>TR</given-names></name><name><surname>Laklai</surname><given-names>H</given-names></name><name><surname>Sugimoto</surname><given-names>H</given-names></name><name><surname>Kahlert</surname><given-names>C</given-names></name><name><surname>Novitskiy</surname><given-names>SV</given-names></name><name><surname>De Jesus-Acosta</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Heidari</surname><given-names>P</given-names></name><name><surname>Mahmood</surname><given-names>U</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Moses</surname><given-names>HL</given-names></name><name><surname>Weaver</surname><given-names>VM</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name><name><surname>LeBleu</surname><given-names>VS</given-names></name><name><surname>Kalluri</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival</article-title><source>Cancer Cell</source><volume>25</volume><fpage>719</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.04.005</pub-id><pub-id pub-id-type="pmid">24856586</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>H</given-names></name><name><surname>Croft</surname><given-names>W</given-names></name><name><surname>Nicol</surname><given-names>SM</given-names></name><name><surname>Margielewska-Davies</surname><given-names>S</given-names></name><name><surname>Powell</surname><given-names>R</given-names></name><name><surname>Cornall</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>SJ</given-names></name><name><surname>Marcon</surname><given-names>F</given-names></name><name><surname>Pugh</surname><given-names>MR</given-names></name><name><surname>Fennell</surname><given-names>É</given-names></name><name><surname>Powell-Brett</surname><given-names>S</given-names></name><name><surname>Mahon</surname><given-names>BS</given-names></name><name><surname>Brown</surname><given-names>RM</given-names></name><name><surname>Middleton</surname><given-names>G</given-names></name><name><surname>Roberts</surname><given-names>K</given-names></name><name><surname>Moss</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Tissue-resident memory T cells in pancreatic ductal adenocarcinoma co-express PD-1 and TIGIT and functional inhibition is reversible by dual antibody blockade</article-title><source>Cancer Immunology Research</source><volume>11</volume><fpage>435</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-22-0121</pub-id><pub-id pub-id-type="pmid">36689623</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piersma</surname><given-names>B</given-names></name><name><surname>Hayward</surname><given-names>MK</given-names></name><name><surname>Weaver</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Fibrosis and cancer: A strained relationship</article-title><source>Biochimica et Biophysica Acta. Reviews on Cancer</source><volume>1873</volume><elocation-id>188356</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbcan.2020.188356</pub-id><pub-id pub-id-type="pmid">32147542</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Fu</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Plasma interleukin-11 (IL-11) levels have diagnostic and prognostic roles in patients with pancreatic cancer</article-title><source>Tumour Biology</source><volume>35</volume><fpage>11467</fpage><lpage>11472</lpage><pub-id pub-id-type="doi">10.1007/s13277-014-2459-y</pub-id><pub-id pub-id-type="pmid">25123265</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Revel</surname><given-names>M</given-names></name><name><surname>Daugan</surname><given-names>MV</given-names></name><name><surname>Sautés-Fridman</surname><given-names>C</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Roumenina</surname><given-names>LT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Complement system: promoter or suppressor of cancer progression</article-title><source>Antibodies</source><volume>9</volume><elocation-id>57</elocation-id><pub-id pub-id-type="doi">10.3390/antib9040057</pub-id><pub-id pub-id-type="pmid">33113844</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risso</surname><given-names>D</given-names></name><name><surname>Ngai</surname><given-names>J</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name><name><surname>Dudoit</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Normalization of RNA-seq data using factor analysis of control genes or samples</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>896</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1038/nbt.2931</pub-id><pub-id pub-id-type="pmid">25150836</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title><italic>limma</italic> powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Research</source><volume>43</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>LA</given-names></name><name><surname>Sethna</surname><given-names>Z</given-names></name><name><surname>Soares</surname><given-names>KC</given-names></name><name><surname>Olcese</surname><given-names>C</given-names></name><name><surname>Pang</surname><given-names>N</given-names></name><name><surname>Patterson</surname><given-names>E</given-names></name><name><surname>Lihm</surname><given-names>J</given-names></name><name><surname>Ceglia</surname><given-names>N</given-names></name><name><surname>Guasp</surname><given-names>P</given-names></name><name><surname>Chu</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Chandra</surname><given-names>AK</given-names></name><name><surname>Waters</surname><given-names>T</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Amisaki</surname><given-names>M</given-names></name><name><surname>Zebboudj</surname><given-names>A</given-names></name><name><surname>Odgerel</surname><given-names>Z</given-names></name><name><surname>Payne</surname><given-names>G</given-names></name><name><surname>Derhovanessian</surname><given-names>E</given-names></name><name><surname>Müller</surname><given-names>F</given-names></name><name><surname>Rhee</surname><given-names>I</given-names></name><name><surname>Yadav</surname><given-names>M</given-names></name><name><surname>Dobrin</surname><given-names>A</given-names></name><name><surname>Sadelain</surname><given-names>M</given-names></name><name><surname>Łuksza</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>N</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Basturk</surname><given-names>O</given-names></name><name><surname>Gönen</surname><given-names>M</given-names></name><name><surname>Katz</surname><given-names>S</given-names></name><name><surname>Do</surname><given-names>RK</given-names></name><name><surname>Epstein</surname><given-names>AS</given-names></name><name><surname>Momtaz</surname><given-names>P</given-names></name><name><surname>Park</surname><given-names>W</given-names></name><name><surname>Sugarman</surname><given-names>R</given-names></name><name><surname>Varghese</surname><given-names>AM</given-names></name><name><surname>Won</surname><given-names>E</given-names></name><name><surname>Desai</surname><given-names>A</given-names></name><name><surname>Wei</surname><given-names>AC</given-names></name><name><surname>D’Angelica</surname><given-names>MI</given-names></name><name><surname>Kingham</surname><given-names>TP</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Sahin</surname><given-names>U</given-names></name><name><surname>Türeci</surname><given-names>Ö</given-names></name><name><surname>Greenbaum</surname><given-names>BD</given-names></name><name><surname>Jarnagin</surname><given-names>WR</given-names></name><name><surname>Drebin</surname><given-names>J</given-names></name><name><surname>O’Reilly</surname><given-names>EM</given-names></name><name><surname>Balachandran</surname><given-names>VP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer</article-title><source>Nature</source><volume>618</volume><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06063-y</pub-id><pub-id pub-id-type="pmid">37165196</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salman</surname><given-names>S</given-names></name><name><surname>Meyers</surname><given-names>DJ</given-names></name><name><surname>Wicks</surname><given-names>EE</given-names></name><name><surname>Lee</surname><given-names>SN</given-names></name><name><surname>Datan</surname><given-names>E</given-names></name><name><surname>Thomas</surname><given-names>AM</given-names></name><name><surname>Anders</surname><given-names>NM</given-names></name><name><surname>Hwang</surname><given-names>Y</given-names></name><name><surname>Lyu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Jackson</surname><given-names>W</given-names></name><name><surname>Dordai</surname><given-names>D</given-names></name><name><surname>Rudek</surname><given-names>MA</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy</article-title><source>The Journal of Clinical Investigation</source><volume>132</volume><elocation-id>e156774</elocation-id><pub-id pub-id-type="doi">10.1172/JCI156774</pub-id><pub-id pub-id-type="pmid">35499076</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Regulation of erythropoiesis by the hypoxia-inducible factor pathway: effects of genetic and pharmacological perturbations</article-title><source>Annual Review of Medicine</source><volume>74</volume><fpage>307</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-042921-102602</pub-id><pub-id pub-id-type="pmid">35773226</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>MW</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>YW</given-names></name><name><surname>Niu</surname><given-names>N</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer</article-title><source>Cancer Letters</source><volume>453</volume><fpage>158</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2019.03.051</pub-id><pub-id pub-id-type="pmid">30954649</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shindo</surname><given-names>K</given-names></name><name><surname>Aishima</surname><given-names>S</given-names></name><name><surname>Ohuchida</surname><given-names>K</given-names></name><name><surname>Fujiwara</surname><given-names>K</given-names></name><name><surname>Fujino</surname><given-names>M</given-names></name><name><surname>Mizuuchi</surname><given-names>Y</given-names></name><name><surname>Hattori</surname><given-names>M</given-names></name><name><surname>Mizumoto</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Oda</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas</article-title><source>Molecular Cancer</source><volume>12</volume><elocation-id>168</elocation-id><pub-id pub-id-type="doi">10.1186/1476-4598-12-168</pub-id><pub-id pub-id-type="pmid">24354864</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>T</given-names></name><name><surname>Barham</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Gicobi</surname><given-names>JK</given-names></name><name><surname>Hirdler</surname><given-names>JB</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Ham</surname><given-names>H</given-names></name><name><surname>Peterson Martinez</surname><given-names>KE</given-names></name><name><surname>Lucien</surname><given-names>F</given-names></name><name><surname>Lavoie</surname><given-names>RR</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Correia</surname><given-names>C</given-names></name><name><surname>Monie</surname><given-names>DD</given-names></name><name><surname>An</surname><given-names>Z</given-names></name><name><surname>Harrington</surname><given-names>SM</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Dronca</surname><given-names>RS</given-names></name><name><surname>Mansfield</surname><given-names>AS</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Markovic</surname><given-names>SN</given-names></name><name><surname>Park</surname><given-names>SS</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>MC</given-names></name><name><surname>Vasmatzis</surname><given-names>G</given-names></name><name><surname>Billadeau</surname><given-names>DD</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Nkg7 is a T-cell-intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy</article-title><source>Cancer Immunology Research</source><volume>10</volume><fpage>162</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-21-0539</pub-id><pub-id pub-id-type="pmid">34911739</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Vonlaufen</surname><given-names>A</given-names></name><name><surname>Phillips</surname><given-names>PA</given-names></name><name><surname>Fiala-Beer</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Biankin</surname><given-names>AV</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Pirola</surname><given-names>RC</given-names></name><name><surname>Wilson</surname><given-names>JS</given-names></name><name><surname>Apte</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Role of pancreatic stellate cells in pancreatic cancer metastasis</article-title><source>The American Journal of Pathology</source><volume>177</volume><fpage>2585</fpage><lpage>2596</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2010.090899</pub-id><pub-id pub-id-type="pmid">20934972</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>LY</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Bai</surname><given-names>XL</given-names></name><name><surname>Pankaj</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>QD</given-names></name><name><surname>Liang</surname><given-names>TB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hypoxia-inducible factor 1α expression and its clinical significance in pancreatic cancer: a meta-analysis</article-title><source>Pancreatology</source><volume>14</volume><fpage>391</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.pan.2014.06.008</pub-id><pub-id pub-id-type="pmid">25278309</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Hao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin</article-title><source>Cancer Research</source><volume>74</volume><fpage>2455</fpage><lpage>2464</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-3009</pub-id><pub-id pub-id-type="pmid">24599125</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Husted</surname><given-names>H</given-names></name><name><surname>Moore</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ramachandran</surname><given-names>V</given-names></name><name><surname>Arumugam</surname><given-names>T</given-names></name><name><surname>Niehrs</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chiao</surname><given-names>P</given-names></name><name><surname>Ling</surname><given-names>J</given-names></name><name><surname>Curran</surname><given-names>MA</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Logsdon</surname><given-names>CD</given-names></name><name><surname>Hwang</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma</article-title><source>Science Translational Medicine</source><volume>10</volume><elocation-id>eaat3487</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aat3487</pub-id><pub-id pub-id-type="pmid">30355799</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Hou</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Prognostic stratification based on HIF-1 signaling for evaluating hypoxic status and immune infiltration in pancreatic ductal adenocarcinomas</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>790661</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.790661</pub-id><pub-id pub-id-type="pmid">34925373</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoico</surname><given-names>E</given-names></name><name><surname>Darra</surname><given-names>E</given-names></name><name><surname>Rizzatti</surname><given-names>V</given-names></name><name><surname>Budui</surname><given-names>S</given-names></name><name><surname>Franceschetti</surname><given-names>G</given-names></name><name><surname>Mazzali</surname><given-names>G</given-names></name><name><surname>Rossi</surname><given-names>AP</given-names></name><name><surname>Fantin</surname><given-names>F</given-names></name><name><surname>Menegazzi</surname><given-names>M</given-names></name><name><surname>Cinti</surname><given-names>S</given-names></name><name><surname>Zamboni</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Adipocytes WNT5a mediated dedifferentiation: a possible target in pancreatic cancer microenvironment</article-title><source>Oncotarget</source><volume>7</volume><fpage>20223</fpage><lpage>20235</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7936</pub-id><pub-id pub-id-type="pmid">26958939</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86125.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Macleod</surname><given-names>Kay F</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024mw5h28</institution-id><institution>University of Chicago</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2023.01.20.524883" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2023.01.20.524883"/></front-stub><body><p>The plasticity and heterogeneity of fibroblasts in the tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) has emerged as a key factor in determining tumor growth and therapeutic response. Here the authors use innovative approaches to combine spatial profiling with single cell transcriptomics to define tumor-proximal populations of fibroblasts that predict clinical outcome. Specifically, elevated expression of HIF-1a and podoplanin predicted worse outcome while inflammatory gene expression correlated with increased survival, suggesting future interventions targeting proximal fibroblast populations to mitigate against PDAC.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86125.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Macleod</surname><given-names>Kay F</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024mw5h28</institution-id><institution>University of Chicago</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Pasca di Magliano</surname><given-names>Marina</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>University of Michigan-Ann Arbor</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2023.01.20.524883">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2023.01.20.524883v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Tony Ng as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Marina Pasca di Magliano (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) It is essential to add the use of additional fibroblast and myeloid markers, as suggested by both reviewers.</p><p>2) If possible, please add an increased analysis of the transcriptomics to include more cells and markers.</p><p>3) Please address reviewers' concerns with interpretation, proper citation, and general text accuracy and presentation.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1) The writing could be improved across the manuscript. There are often words or letters missing in the text.</p><p>2) The abstract reads as if the authors generated both the spatial and single-cell transcriptomics data by themselves from the same patients. This is misleading and should be amended.</p><p>3) Interestingly, the authors find expression of inflammatory genes in tumor distal, aSMA+ regions. This could indicate the existence of a potential hybrid myofibroblastic/inflammatory CAF state.</p><p>4) It would have been helpful if the authors included other canonical fibroblast markers in their nCounter analysis, such as PDGFRA, aSMA, and COL1A1. THY1 is not necessarily a canonical fibroblast marker and is rather expressed in subsets of myofibroblasts.</p><p>5) Line 198/199 – THY1 is repeated.</p><p>6) Line 236 – positive correlation of C3 expression with THY1 expression is NOT a confirmation for it to be fibroblast-derived, but rather an indication. Also, only THY1 but not other fibroblast marker genes (as mentioned in line 237) was used in the correlation analysis.</p><p>7) Line 239 – STAT3 and IL6 expression COULD be explained by their presence within inflammatory CAFs (their presence on iCAFs does not explain it).</p><p>8) The retinoic acid signature observed in tumor-distal fibroblasts could also indicate that these cells are less activated, given that quiescent stellate cells express high levels of retinoic acid metabolism genes.</p><p>9) In Figure 4F it looks like there are two distinct clusters within the sc-distant cluster, and the second one looks much more like the sc-proximal cluster. The authors should explain or represent this better.</p><p>10) Sup. Figure 7C is never mentioned in the text and is confusing. The authors should incorporate it in the text and explain what is shown in this panel.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Specific comments:</p><p>1) The authors select regions of interest (ROIs) that are proximal or distant from cancer cells; a more specific definition of how &quot;proximal&quot; and &quot;distal&quot; are defined would be useful. In addition, there are two potential issues to address or at least discuss: 1) the 2D nature of a tissue section makes it impossible to determine whether cancer cells are present in the same area but above or below the plane of the section. 2) the samples are described as biopsies of resected tumors: the authors should discuss whether the biopsy is likely to reflect the whole tumor or discuss the potential confounding effect of tumor heterogeneity.</p><p>2) Some of the markers of the distal stroma are also expressed by other cell types – for instance, complement genes are associated with macrophages. In order to confirm that they are indeed expressed in fibroblasts, the authors could consider co-immunofluorescent staining with lineage markers for fibroblasts and myeloid cells, respectively.</p><p>It is not clear what the take home of Figure 4F is; what kind of differences in transcription factor signatures distinguish the different fibroblast populations is not clear.</p><p>3) Figure 5 seems somewhat disjointed from the rest of the manuscript – it is unclear whether gene signatures that predict poor outcomes are linked to a specific geographic distribution of different types of fibroblasts, or whether it is simply the prevalence of each type that affects tumor characteristics.</p><p>4) The authors should discuss their findings in light of recent literature that either supports or contradicts the link between myCAFS and outcome, as this is an area of active investigation.</p><p>5) In Figure 2B, the colors of the tumor and proximal stroma are difficult to distinguish from one another.</p><p>6) Figure 2 (and other figures as well) many of the graphs and text is too small to clearly read. For the heat map, one option would be to highlight key genes labelling them with a larger font. The whole list could be moved to supplemental information. Some of the other graphs could be enlarged.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86125.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) It is essential to add the use of additional fibroblast and myeloid markers, as suggested by both reviewers.</p></disp-quote><p>Thank you for this advice. We have now added a range of new fibroblast and myeloid genes in the analysis using the extensive transcriptional data. This work is fully discussed in the revision and we are confident that this enhances the discovery outcomes considerably.</p><p>Unfortunately, further antibody or RNA probes cannot be added to the Nanostring experimental study as this is fully completed.</p><disp-quote content-type="editor-comment"><p>2) If possible, please add an increased analysis of the transcriptomics to include more cells and markers.</p></disp-quote><p>Thank you, we have now added additional fibroblast markers to Figure 4 confirming that the fibroblast populations are indeed expressing the canonical fibroblast marker genes <italic>DCN</italic>, <italic>LUM</italic> and <italic>THY1. LUM</italic> in particular has been shown to be highly specific to PDAC fibroblast cells (PMID: 34035226) and consistent with this, we observe high expression of this marker in our fibroblast scRNA data. Additionally, we have included the generic CAF marker gene <italic>COL1A2</italic> which again shows widespread expression in our fibroblast population.</p><disp-quote content-type="editor-comment"><p>3) Please address reviewers' concerns with interpretation, proper citation, and general text accuracy and presentation.</p></disp-quote><p>Thank you. We have substantially revised the manuscript and added a range of important additional citations.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1) The writing could be improved across the manuscript. There are often words or letters missing in the text.</p></disp-quote><p>We thank the reviewer for this comment and have edited the manuscript to make the required corrections to these oversights.</p><disp-quote content-type="editor-comment"><p>2) The abstract reads as if the authors generated both the spatial and single-cell transcriptomics data by themselves from the same patients. This is misleading and should be amended.</p></disp-quote><p>Thank you for this point for which we apologise. This has now been amended.</p><disp-quote content-type="editor-comment"><p>3) Interestingly, the authors find expression of inflammatory genes in tumor distal, aSMA+ regions. This could indicate the existence of a potential hybrid myofibroblastic/inflammatory CAF state.</p></disp-quote><p>Thank you for this insight which may be reflective of the remarkable plasticity of fibroblasts and could represent an important transition subset. We have now added this information to the Discussion.</p><disp-quote content-type="editor-comment"><p>4) It would have been helpful if the authors included other canonical fibroblast markers in their nCounter analysis, such as PDGFRA, aSMA, and COL1A1. THY1 is not necessarily a canonical fibroblast marker and is rather expressed in subsets of myofibroblasts.</p></disp-quote><p>We thank the reviewer for highlighting the limitation of reliance on a single marker for a heterogenous population of cells. However, we would point out that we have used THY1, FAP and PDPN to identify fibroblast subsets.</p><p>We agree that THY1 is not a classical fibroblast marker and we have added this to the text. However, we find (Figure 4C) that THY1 is expressed in the majority of fibroblasts (as identified in the scRNAseq dataset) with average expression level that is lower in tumor-proximal stroma.</p><disp-quote content-type="editor-comment"><p>5) Line 198/199 – THY1 is repeated.</p></disp-quote><p>Thank you, this has now been corrected.</p><disp-quote content-type="editor-comment"><p>6) Line 236 – positive correlation of C3 expression with THY1 expression is NOT a confirmation for it to be fibroblast-derived, but rather an indication. Also, only THY1 but not other fibroblast marker genes (as mentioned in line 237) was used in the correlation analysis.</p></disp-quote><p>Thank you for highlighting this important point and we agree that this correlation alone is not confirmation. We have edited the text to read that the correlation of C3 with THY1, SFRP2, PDPN and FAP expression, and concurrent lack of correlation with CD68, is an indication that the C3 expression is likely to be fibroblast, rather than monocyte, derived. It is reassuring that significant positive correlation is specifically observed within distant stroma regions between C3 and additional Fibroblast marker genes (SFRP2 PDPN and FAP) and these have also been added to Figure 3 —figure supplement 1.</p><disp-quote content-type="editor-comment"><p>7) Line 239 – STAT3 and IL6 expression COULD be explained by their presence within inflammatory CAFs (their presence on iCAFs does not explain it).</p></disp-quote><p>Thank you, we have reworded this sentence to reflect that STAT3 and IL6 expression could be explained by presence within iCAFs.</p><disp-quote content-type="editor-comment"><p>8) The retinoic acid signature observed in tumor-distal fibroblasts could also indicate that these cells are less activated, given that quiescent stellate cells express high levels of retinoic acid metabolism genes.</p></disp-quote><p>We thank the reviewer for this interesting insight. We have now added this point to the Discussion.</p><disp-quote content-type="editor-comment"><p>9) In Figure 4F it looks like there are two distinct clusters within the sc-distant cluster, and the second one looks much more like the sc-proximal cluster. The authors should explain or represent this better.</p></disp-quote><p>We thank the reviewer for this comment. We agree that the GSVA profiles might suggest a potential subcluster within the sc-distant cluster that has a profile resembling the sc-proximal cells. The initial clusters were generated in an unsupervised manner to avoid any bias in defining the number of clusters that should be produced. One potential explanation is that this represents a transitional fibroblast state at the interface of the distal and proximal clusters. We have added an explanation of this observation to the text.</p><disp-quote content-type="editor-comment"><p>10) Sup. Figure 7C is never mentioned in the text and is confusing. The authors should incorporate it in the text and explain what is shown in this panel.</p></disp-quote><p>Thank you, and we apologise for the lack of reference to figure within the text.</p><p>This supplementary figure panel (now labelled as Figure 5 —figure supplement 1C) shows an analysis of proximal-to-distant expression gradients in the stromal regions as it is possible that spatial gradients in expression may also provide indication of prognosis. Indeed, we identify genes whose expression gradients are significantly different when stratified by 1 vs 3 year survival. This is now referred to and explained in the text.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Specific comments:</p><p>1) The authors select regions of interest (ROIs) that are proximal or distant from cancer cells; a more specific definition of how &quot;proximal&quot; and &quot;distal&quot; are defined would be useful. In addition, there are two potential issues to address or at least discuss: 1) the 2D nature of a tissue section makes it impossible to determine whether cancer cells are present in the same area but above or below the plane of the section. 2) the samples are described as biopsies of resected tumors: the authors should discuss whether the biopsy is likely to reflect the whole tumor or discuss the potential confounding effect of tumor heterogeneity.</p></disp-quote><p>Thank you. We have expanded the Materials and methods section to include a more detailed description of how proximal and distal regions are defined. Point 1 has now been addressed in the Discussion. Point 2 has been addressed by further emphasising the use of multiple regions of interest per domain across the tissue section in the <italic>Material and Method</italic>s section. Furthermore, we have also added this point to the Discussion as a limitation of the study.</p><disp-quote content-type="editor-comment"><p>2) Some of the markers of the distal stroma are also expressed by other cell types – for instance, complement genes are associated with macrophages. In order to confirm that they are indeed expressed in fibroblasts, the authors could consider co-immunofluorescent staining with lineage markers for fibroblasts and myeloid cells, respectively.</p></disp-quote><p>Thank you for this advice. We have now considerably extended the transcriptional analysis and this further supports a fibroblast origin. However, we agree with the reviewer that this is not definitive evidence of co-expression. It is possible that technologies with enhanced resolution, such as the CosMx system, may be able to overcome this. We were not able to undertake co-immunofluorescence studies but have added this to the text as an important ambition for future studies.</p><disp-quote content-type="editor-comment"><p>It is not clear what the take home of Figure 4F is; what kind of differences in transcription factor signatures distinguish the different fibroblast populations is not clear.</p></disp-quote><p>We thank the reviewer for this comment. Figure 4F highlights the main functional and TF regulon differences between sc-proximal and sc-distant cells. This informs the likely dominant transcription factors governing the characterised differential gene expression profiles and functional activities of sc-proximal vs sc-distant fibroblasts. We have expanded the text in this section to clarify.</p><disp-quote content-type="editor-comment"><p>3) Figure 5 seems somewhat disjointed from the rest of the manuscript – it is unclear whether gene signatures that predict poor outcomes are linked to a specific geographic distribution of different types of fibroblasts, or whether it is simply the prevalence of each type that affects tumor characteristics.</p></disp-quote><p>Thank you. Figure 5 is included here as it identifies genes associated with survival outcome and interrogates the likely spatially-defined source of such signals. Firstly the-prognosis associated genes are identified by differential expression analysis including all region data stratified by good (3yr) and bad (1yr) survival (Figure 5A). The likely spatially-defined source of prognostic gene signal is then interrogated by distinct analysis comparing good vs bad survival groupings using Immune region or stroma region data only. Any gene found to be significantly divergent (prognosis-associated) from either analysis is visualised in Figure 5C to assess the relative Immune-region and Stromal-region contribution. To further interrogate the source of stromal prognostic gene signals, again, distinct good vs bad differentially expressed genes were identified using either only tumor-proximal or tumor-distant region data (Figure 5D). To summarise the spatially-defined region-specific and non-region specific prognosis associated genes, the overlap of any within PS, DS or Immune region significant hit was visualised in Figure 5E. We have added further text in the manuscript to clarify the inclusion of these analyses.</p><disp-quote content-type="editor-comment"><p>4) The authors should discuss their findings in light of recent literature that either supports or contradicts the link between myCAFS and outcome, as this is an area of active investigation.</p></disp-quote><p>Thank you. We have now extended the discussion considerably and refer the reader to an excellent recent review on PDAC in CAF.</p><disp-quote content-type="editor-comment"><p>5) In Figure 2B, the colors of the tumor and proximal stroma are difficult to distinguish from one another.</p></disp-quote><p>Thank you, colours have now been changed to make them more distinguishable.</p><disp-quote content-type="editor-comment"><p>6) Figure 2 (and other figures as well) many of the graphs and text is too small to clearly read. For the heat map, one option would be to highlight key genes labelling them with a larger font. The whole list could be moved to supplemental information. Some of the other graphs could be enlarged.</p></disp-quote><p>We thank the reviewer for this comment. Figures have now been edited to increase graph and text sizes where possible such that minimum text size is 6pt.</p></body></sub-article></article>